OPKO Health (OPK) 10-Q 5 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Opko Health, Inc.
Entity Central Index Key	944,809
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		463,617,245

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	[1]	$ 221,217	$ 96,907
Accounts receivable, net	[1]	26,980	19,969
Inventory, net	[1]	20,519	16,604
Prepaid expenses and other current assets	[1]	9,623	9,389
Total current assets	[1]	278,339	142,869
Property, plant, equipment, and investment properties, net	[1]	23,405	16,411
Intangible assets, net	[1]	94,247	62,649
In-process research and development	[1]	812,446	793,152
Goodwill	[1]	289,607	224,292
Investments, net	[1]	21,434	22,453
Other assets	[1]	6,013	5,838
Total assets	[1]	1,525,491	1,267,664
Current liabilities:
Accounts payable	[1]	16,039	8,744
Accrued expenses	[1]	149,843	60,912
Current portion of lines of credit and notes payable	[1]	14,599	13,455
Total current liabilities	[1]	180,481	83,111
2033 Senior Notes, net of discount and estimated fair value of embedded derivatives	[1]	109,203	131,454
Other long-term liabilities, principally deferred revenue and deferred tax liabilities	[1]	408,821	217,358
Total long-term liabilities	[1]	518,024	348,812
Total liabilities	[1]	698,505	431,923
Equity:
Common Stock - $0.01 par value, 750,000,000 shares authorized; 464,567,632 and 433,421,677 shares issued at June 30, 2015 and December 31, 2014, respectively	[1]	4,646	4,334
Treasury Stock - 1,120,367 and 1,245,367 shares at June 30, 2015 and December 31, 2014, respectively	[1]	(3,645)	(4,051)
Additional paid-in capital	[1]	1,687,389	1,529,096
Accumulated other comprehensive income (loss)	[1]	(18,880)	(12,392)
Accumulated deficit	[1]	(834,721)	(674,843)
Total shareholders’ equity attributable to OPKO	[1]	834,789	842,144
Noncontrolling interests	[1]	(7,803)	(6,403)
Total shareholders’ equity	[1]	826,986	835,741
Total liabilities and equity	[1]	$ 1,525,491	$ 1,267,664
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common Stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized (in shares)	750,000,000	750,000,000
Common Stock, shares issued (in shares)	464,567,632	433,421,677
Treasury stock, shares (in shares)	1,120,367	1,245,367
Total assets in variable interest entity	$ 7.1	$ 7.6
Total liability in variable interest entity	$ 12.7	$ 12.1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Products	$ 22,848	$ 21,392	$ 38,334	$ 41,219
Revenue from services	1,908	2,153	3,977	4,123
Revenue from transfer of intellectual property	17,673	0	30,202	476
Total revenues	42,429	23,545	72,513	45,818
Costs and expenses:
Costs of revenues	14,434	12,565	24,755	24,955
Selling, general and administrative	20,937	14,874	38,382	28,686
Research and development	29,570	16,234	55,072	37,227
In-process research and development	0	10,055	0	10,055
Contingent consideration	(339)	1,876	4,836	4,486
Amortization of intangible assets	3,236	2,826	5,901	5,569
Grant repayment	0	0	25,889	0
Total costs and expenses	67,838	58,430	154,835	110,978
Operating loss	(25,409)	(34,885)	(82,322)	(65,160)
Other income and (expense), net:
Interest income	5	7	12	48
Interest expense	(986)	(4,685)	(3,551)	(8,171)
Fair value changes of derivative instruments, net	(16,556)	10,967	(66,344)	594
Other income (expense), net	760	2,990	(748)	4,666
Other income and (expense), net	(16,777)	9,279	(70,631)	(2,863)
Loss before income taxes and investment losses	(42,186)	(25,606)	(152,953)	(68,023)
Income tax benefit (provision)	(251)	(101)	(5,760)	(714)
Loss before investment losses	(42,437)	(25,707)	(158,713)	(68,737)
Loss from investments in investees	(804)	(370)	(2,565)	(2,426)
Net loss	(43,241)	(26,077)	(161,278)	(71,163)
Less: Net loss attributable to noncontrolling interests	(475)	(597)	(1,400)	(1,137)
Net loss attributable to common shareholders	$ (42,766)	$ (25,480)	$ (159,878)	$ (70,026)
Net loss per share (usd per share)	$ (0.09)	$ (0.06)	$ (0.35)	$ (0.17)
Weighted average number of common shares outstanding, basic and diluted (shares)	462,253,161	413,339,679	454,361,137	413,125,932

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net loss	$ (43,241)	$ (26,077)	$ (161,278)	$ (71,163)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation and other comprehensive income (loss) from equity investments	(694)	188	(4,547)	(1,613)
Available for sale investments:
Change in unrealized gain (loss), net of tax	(682)	(1,283)	(1,941)	(948)
Less: reclassification adjustments for (gains) losses included in net loss, net of tax	0	0	0	(553)
Comprehensive loss	(44,617)	(27,172)	(167,766)	(74,277)
Less: Comprehensive loss attributable to noncontrolling interest	(475)	(597)	(1,400)	(1,137)
Comprehensive loss attributable to common shareholders	$ (44,142)	$ (26,575)	$ (166,366)	$ (73,140)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015		Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (161,278)		$ (71,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,685		7,591
Non-cash interest on 2033 Senior Notes	1,681		3,557
Amortization of deferred financing costs	895		1,807
Losses from investments in investees	2,565		2,426
Equity-based compensation – employees and non-employees	14,090		6,993
(Recovery of) provision for bad debts	626		(68)
Provision for inventory obsolescence	710		583
Revenue from receipt of equity	(120)		(120)
Realized gain on sale of equity securities	(216)		(1,274)
(Gain) loss on conversion of 3.00% convertible senior notes	291		(2,668)
Change in fair value of derivative instruments	66,344		(594)
In-process research and development	0		10,055
Change in fair value of contingent consideration	4,836		4,486
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable	(4,812)		(4,321)
Inventory	(3,257)		(1,413)
Prepaid expenses and other current assets	1,142		3,466
Other assets	(512)		3,911
Accounts payable	7,101		(3,308)
Foreign currency measurement	300		(824)
Deferred revenue	263,926		(846)
Accrued expenses and other liabilities	2,741		(2,817)
Net cash provided by (used in) operating activities	204,738		(44,541)
Cash flows from investing activities:
Investments in investees	(2,345)		(500)
Proceeds from sale of equity securities	0		1,331
Acquisition of businesses, net of cash	(94,674)		(1,695)
Capital expenditures	(1,439)		(2,467)
Net cash used in investing activities	(98,458)		(3,331)
Cash flows from financing activities:
Proceeds from the exercise of Common Stock options and warrants	17,366		2,747
Cash from non-controlling interest	100		0
Contingent consideration payments	0		(6,435)
Borrowings on lines of credit	11,038		14,258
Repayments of lines of credit	(10,022)		(14,571)
Net cash provided by financing activities	18,482		(4,001)
Effect of exchange rate on cash and cash equivalents	(452)		85
Net increase (decrease) in cash and cash equivalents	124,310		(51,788)
Cash and cash equivalents at beginning of period	96,907	[1]	185,798
Cash and cash equivalents at end of period	221,217	[1]	134,010
SUPPLEMENTAL INFORMATION:
Interest paid	1,724		2,771
Income taxes paid, net	757		796
Pharmsynthez common stock received	0		6,264
Non-cash financing:
Common Stock options and warrants, surrendered in net exercise	14,239		3,493
OPKO Health Europe
Issuance of Common Stock to acquire:
OPKO Uruguay Ltda.	1,813		0
OPKO Uruguay Ltda.
Issuance of Common Stock to acquire:
OPKO Uruguay Ltda.	0		159
Inspiro
Issuance of Common Stock to acquire:
OPKO Uruguay Ltda.	0		8,566
EirGen Pharma Ltd
Issuance of Common Stock to acquire:
OPKO Uruguay Ltda.	33,569		0
Conversion of Senior Notes
Non-cash financing:
2033 Senior Notes	$ 92,172		$ 95,665
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Jun. 30, 2015	Jan. 31, 2013
Notes | Notes Due February 1, 2033
Convertible senior notes interest rate	3.00%	3.00%

Business and Organization

Business and Organization	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND ORGANIZATION	BUSINESS AND ORGANIZATION We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies. We are developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. We plan to commercialize these solutions on a global basis in large and high growth markets, including emerging markets. On June 3, 2015, we entered into an agreement and plan of merger pursuant to which we agreed to acquire Bio-Reference Laboratories, Inc. ("Bio-Reference"). Bio-Reference is the third largest full service clinical laboratory in the United States and is known for its innovative technological solutions and pioneering leadership in the areas of genomics and genetic sequencing. Under the terms of the agreement, which has been approved by the Boards of Directors of both companies, holders of Bio-Reference common stock will receive 2.75 shares of OPKO common stock for each share of Bio-Reference common stock. Assuming a closing price of $16.74 per share of OPKO common stock, the transaction is valued at approximately $1.3 billion , or $46.04 per share of Bio-Reference common stock. We expect the transaction to be completed during the second half of 2015. Closing of the transaction is subject to approval of Bio-Reference’s shareholders and other customary conditions. Although we have entered into the merger agreement, there is no guarantee that the merger will be completed. A meeting of the shareholders of Bio-Reference will be held on August 20, 2015 to vote on a proposal to approve and adopt the merger agreement and approve the merger. On May 5, 2015, we acquired all of the issued and outstanding shares of EirGen, a specialty pharmaceutical company incorporated in Ireland focused on the development and commercial supply of high potency, high barrier to entry pharmaceutical products, for $133.8 million in the aggregate. We acquired the outstanding shares of EirGen for approximately $100.2 million in cash and delivered 2,420,487 shares of our Common Stock valued at approximately $33.6 million based on the closing price per share of our Common Stock as reported by the New York Stock Exchange on the closing date of the acquisition, $13.88 per share. We own established pharmaceutical platforms in Chile, Spain, Mexico, and Uruguay, which are generating revenue and which we expect to facilitate future market entry for our products currently in development. In addition, we have a development and commercial supply pharmaceutical company and a global supply chain operation and holding company in Ireland. We own a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products. In the U.S., we own a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, as amended (“CLIA”), with a urologic focus that generates revenue and serves as the commercial platform for the U.S. launch of the 4Kscore test to improve cancer risk stratification of patient candidates prior to prostate biopsy. We are incorporated in Delaware and our principal executive offices are located in leased offices in Miami, Florida. We lease office and lab space in Jupiter and Miramar, Florida, and Nes Ziona, Israel, which is where our molecular diagnostics research and development, oligonucleotide research and development and carboxyl terminal peptide research and development operations are based, respectively. We lease office, manufacturing and warehouse space in Woburn, Massachusetts for our point-of-care diagnostics business, and in Nesher, Israel for our API business. We lease laboratory and office space in Nashville, Tennessee, Burlingame, California, and Miramar, Florida for our CLIA-certified laboratory business. Our Chilean and Uruguayan operations are located in leased offices and warehouse facilities in Santiago and Montevideo, respectively. Our Mexican operations are based in owned offices, an owned manufacturing facility and a leased warehouse facility in Guadalajara and in leased offices in Mexico City. Our Spanish operations are based in owned offices in Barcelona, in an owned manufacturing facility in Banyoles and a leased warehouse facility in Palol de Revardit. Our Brazilian operations are located in leased offices in Sao Paulo. Our Irish operations are located in leased offices in Waterford and Dublin.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three and six months ended June 30, 2015 , are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2015 or any future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014 . Principles of consolidation . The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly-owned subsidiaries and a variable interest entity in which we are deemed to be the primary beneficiary. All intercompany accounts and transactions are eliminated in consolidation. Use of estimates . The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates. Cash and cash equivalents. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. Inventories . Inventories are valued at the lower of cost or market (net realizable value). Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost or market. Pre-launch inventories . We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval. The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever. This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity. In accordance with our policy, this pre-launch inventory is expensed. At June 30, 2015 and December 31, 2014 , there were no pre-launch inventories. Goodwill and intangible assets . Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired when accounted for by the purchase method of accounting and arose from our acquisitions of Pharma Genexx, S.A. (“OPKO Chile”), Pharmacos Exakta S.A. de C.V. (“OPKO Mexico”), CURNA, Inc. (“CURNA”), Claros Diagnostics, Inc. (“OPKO Diagnostics”), FineTech Pharmaceuticals, Ltd. (“FineTech”), ALS Distribuidora Limitada (“ALS”), Farmadiet Group Holding, S.L. (“OPKO Health Europe”), previously known as OPKO Spain, Prost-Data, Inc. (“OPKO Lab”), Cytochroma Inc. (“OPKO Renal”), Silcon Comércio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos Ltda. (“OPKO Brazil”), PROLOR Biotech, Inc. (“OPKO Biologics”) and EirGen Pharma Limited ("EirGen"). Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions at June 30, 2015 and December 31, 2014 were $1.2 billion and $1.1 billion , respectively. Assets acquired and liabilities assumed in business combinations, licensing and other transactions are recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. We determined the fair value of intangible assets, including IPR&D, using the “income method.” Goodwill is tested at least annually for impairment, or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value. Intangible assets are tested for impairment whenever events or changes in circumstances warrant a review, although IPR&D is required to be tested at least annually until the project is completed or abandoned. Upon obtaining regulatory approval, the IPR&D asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the IPR&D asset is charged to expense. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, currently ranging from 3 to 20 years, and review for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense was $5.9 million and $5.6 million for the six months ended June 30, 2015 and 2014, respectively. Fair value measurements . The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term maturities of these instruments. Investments that are considered available for sale as of June 30, 2015 and December 31, 2014, are carried at fair value. Short-term investments, which we invest in from time to time, include bank deposits, corporate notes, U.S. treasury securities and U.S. government agency securities with original maturities of greater than 90 days and remaining maturities of less than one year . Long-term investments include corporate notes, U.S. treasury securities and U.S. government agency securities with maturities greater than one year . In evaluating fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 8. Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as contingent consideration income. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position. Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations, when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet specific hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At June 30, 2015 and December 31, 2014 , our forward contracts for inventory purchases did not meet the hedge effectiveness requirements to be designated as hedges. Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 9. Revenue recognition. Generally, we recognize revenue from product sales when goods are shipped and title and risk of loss transfer to our customers. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and management’s evaluation of specific factors that may increase or decrease the risk of product returns. Revenue for laboratory services is recognized on the accrual basis at the time test results are reported, which approximates when services are provided. Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services under third-party payer programs are included in revenue net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated program payment amounts. Adjustments to the estimated payment amounts based on final settlement with the programs are recorded upon settlement as an adjustment to revenue. Revenue from transfer of intellectual property includes revenue related to the sale, license or transfer of intellectual property such as upfront license payments, license fees and milestone payments received through our license, collaboration and commercialization agreements. We analyze our multiple-element arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. Non-refundable license fees for the out-license of our technology are recognized depending on the provisions of each agreement. We recognize non-refundable upfront license payments as revenue upon receipt if the license has standalone value and qualifies for treatment as a separate unit of accounting under multiple-element arrangement guidance. License fees with ongoing involvement or performance obligations that do not have standalone value are recorded as deferred revenue, included in Accrued expenses or Other long-term liabilities, when received and generally are recognized ratably over the period of such performance obligations only after both the license period has commenced and we have delivered the technology. The assessment of our obligations and related performance periods requires significant management judgment. If an agreement contains research and development obligations, the relevant time period for the research and development phase is based on management estimates and could vary depending on the outcome of clinical trials and the regulatory approval process. Such changes could materially impact the revenue recognized, and as a result, management reviews the estimates related to the relevant time period of research and development on a quarterly basis. For the three and six months ended June 30, 2015 , revenue from transfer of intellectual property includes $17.7 million and $30.2 million , respectively, of revenue related to the Pfizer Transaction. Refer to Note 12. Revenue from milestone payments related to arrangements under which we have continuing performance obligations are recognized as Revenue from transfer of intellectual property upon achievement of the milestone only if all of the following conditions are met: the milestone payments are non-refundable; there was substantive uncertainty at the date of entering into the arrangement that the milestone would be achieved; the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item by the vendor; the milestone relates solely to past performance; and the amount of the milestone is reasonable in relation to the effort expended or the risk associated with the achievement of the milestone. If any of these conditions are not met, the milestone payments are not considered to be substantive and are, therefore, deferred and recognized as Revenue from transfer of intellectual property over the term of the arrangement as we complete our performance obligations. Total deferred revenue included in Accrued expenses and Other long-term liabilities was $272.4 million and $6.7 million at June 30, 2015 and December 31, 2014 , respectively. The deferred revenue balance at June 30, 2015 relates primarily to the Pfizer Transaction. Refer to Note 12. Allowance for doubtful accounts . We assess the collectability of accounts receivable balances by considering factors such as historical experience, customer credit worthiness, the age of accounts receivable balances and current economic conditions and trends that may affect a customer's ability to pay. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. Our reported net loss is directly affected by our estimate of the collectability of accounts receivable. The amount of the allowance for doubtful accounts was $2.1 million and $1.9 million at June 30, 2015 and December 31, 2014 , respectively. Equity-based compensation. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits, realized from the exercise of stock options as a financing cash inflow and as a reduction of taxes paid in cash flow from operations. Equity-based compensation arrangements to non-employees are recorded at their fair value on the measurement date. The measurement of equity-based compensation to non-employees is subject to periodic adjustment as the underlying equity instruments vest. During the six months ended June 30, 2015 and 2014, we recorded $14.1 million and $7.0 million , respectively, of equity-based compensation expense. Research and development expenses. Research and development expenses include external and internal expenses, partially offset by third-party grants and fundings arising from collaboration agreements. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and stock-based compensation expense. Other unallocated internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract. We record expense for in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining useful life. Segment reporting . Our chief operating decision-maker (“CODM”) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceutical segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Variable interest entities . The consolidation of variable interest entities (“VIE”) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 5. Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or investments available for sale based on our percentage of ownership and whether we have significant influence over the operations of the investees. Investments for which it is not practical to estimate fair value and which we do not have significant influence are accounted for as cost method investments. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 5. For investments classified as available for sale, we record changes in their fair value as unrealized gain or loss in Other comprehensive income (loss) based on their closing price per share at the end of each reporting period. Refer to Note 5. Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Income tax expense was primarily attributable to taxable income recognized from the Pfizer Transaction and related transactions during the six months ended June 30, 2015 . Refer to Note 12. Included in income tax expense is an accrual of $2.3 million related to uncertain tax positions involving income recognition. We recognize that local tax law is inherently complex and the local taxing authorities may not agree with certain tax positions taken. Consequently, it is reasonably possible that the ultimate resolution of these matters in any jurisdiction may be significantly more or less than estimated. We evaluated the estimated tax exposure for a range of current likely outcomes to be from $0 to approximately $50.0 million and recorded our accrual to reflect our best expectation of ultimate resolution. Recent accounting pronouncements. In May 2014, the FASB issued Accounting Standards Update (“ASU”), ASU No. 2014-09, "Revenue from Contracts with Customers." ASU No. 2014-09 clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. ASU No. 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Companies can choose to apply the ASU using either the full retrospective approach or a modified retrospective approach. We are currently evaluating both methods of adoption and the impact that the adoption of this ASU will have on our Condensed Consolidated Financial Statements. In June 2014, the FASB issued ASU No. 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (a consensus of the FASB Emerging Issues Task Force)." ASU No. 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU No. 2014-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Earlier adoption is permitted. The amendments can be applied either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards. We expect to apply the ASU prospectively and do not expect the adoption to have an impact on our Condensed Consolidated Financial Statements. In August 2014, the FASB issued ASU No. 2014-15, "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern," to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on our Condensed Consolidated Financial Statements will be material. In February 2015, the FASB issued ASU No. 2015-02, "Consolidation (Topic 810)," which amends current consolidation guidance including changes to both the variable and voting interest models used by companies to evaluate whether an entity should be consolidated. The requirements from ASU 2015-02 are effective for interim and annual periods beginning after December 15, 2015, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Basic loss per share is computed by dividing our net loss by the weighted average number of shares outstanding during the period. Diluted loss per share is computed by dividing our net loss increased by dividends on preferred stock by the weighted average number of shares outstanding and the impact of all dilutive potential common shares, primarily stock options. The dilutive impact of stock options and warrants is determined by applying the “treasury stock” method. In the periods in which their effect would be antidilutive, no effect has been given to outstanding options, warrants or convertible Preferred Stock in the diluted computation. Potentially dilutive shares issuable pursuant to the 2033 Senior Notes (defined in Note 6) were not included in the computation of net loss per share for the three and six months ended June 30, 2015 , because their inclusion would be antidilutive. A total of 11,261,582 and 29,132,527 potential shares of Common Stock have been excluded from the calculation of diluted net loss per share for the three months ended June 30, 2015 and 2014, respectively, because their inclusion would be antidilutive. A total of 14,375,502 and 29,503,319 potential shares of Common Stock have been excluded from the calculation of diluted net loss per share for the six months ended June 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive. During the three months ended June 30, 2015 , 2,106,679 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 2,106,634 shares of Common Stock. Of the 2,106,679 Common Stock options and Common Stock warrants exercised, 45 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements. During the six months ended June 30, 2015 , 24,168,461 Common Stock options and Common Stock warrants to purchase shares of our Common Stock were exercised, resulting in the issuance of 22,635,661 shares of Common Stock. Of the 24,168,461 Common Stock options and Common Stock warrants exercised, 1,206,654 shares of Common Stock were surrendered in lieu of a cash payment via the net exercise feature of the agreements.

Composition of Certain Financia

Composition of Certain Financial Statement Captions	6 Months Ended
	Jun. 30, 2015
Compositions of Certain Financial Statement Captions [Abstract]
COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS	COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS (In thousands) June 30, December 31, Accounts receivable, net Accounts receivable $ 29,045 $ 21,875 Less: allowance for doubtful accounts (2,065 ) (1,906 ) $ 26,980 $ 19,969 Inventories, net Finished products $ 13,830 $ 12,116 Work in-process 1,619 1,011 Raw materials 5,782 4,116 Less: inventory reserve (712 ) (639 ) $ 20,519 $ 16,604 Prepaid expenses and other current assets Prepaid supplies $ 1,441 $ 1,123 Prepaid insurance 613 968 Other receivables 1,107 669 Taxes recoverable 3,074 2,417 Other 3,388 4,212 $ 9,623 $ 9,389 Intangible assets, net: Technologies $ 52,287 $ 52,508 Customer relationships 55,750 22,108 Product registrations 8,088 8,763 Trade names 3,411 3,483 Covenants not to compete 8,620 8,639 Other 4,889 1,079 Less: accumulated amortization (38,798 ) (33,931 ) $ 94,247 $ 62,649 Accrued expenses: Taxes payable $ 2,592 $ 77 Deferred revenue 75,159 4,185 Clinical trials 8,534 8,643 Professional fees 1,724 1,860 Employee benefits 5,456 4,127 Contingent consideration 41,146 27,352 Other 15,232 14,668 $ 149,843 $ 60,912 (In thousands) June 30, December 31, Other long-term liabilities: Contingent consideration – OPKO Renal $ 19,183 $ 36,529 Contingent consideration – OPKO Health Europe 225 254 Contingent consideration – OPKO Diagnostics 13,342 6,992 Contingent consideration – CURNA 433 440 Mortgages and other debts payable 2,148 2,434 Deferred tax liabilities 172,458 167,153 Deferred revenue 197,279 2,526 Other 3,753 1,030 $ 408,821 $ 217,358 All of the intangible assets and goodwill acquired relate to our acquisitions of OPKO Chile, including the intangible assets and goodwill related to the ALS acquisition, OPKO Mexico, CURNA, OPKO Diagnostics, FineTech, OPKO Health Europe, OPKO Lab, OPKO Brazil, OPKO Renal, OPKO Biologics, OPKO Uruguay Ltda., EirGen and SciVac, a consolidated VIE. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in the U.S., Chile, Canada, Mexico, Spain, Ireland, or Israel. At June 30, 2015 , the changes in value of the intangible assets and goodwill are primarily due to the acquisition of EirGen and foreign currency fluctuations between the Chilean and Mexican pesos, the Euro and the Shekel against the U.S. dollar. The following table reflects the changes in Goodwill during the six months ended June 30, 2015 . 2015 (In thousands) Balance at January 1st Acquisitions Foreign exchange Balance at June 30th Pharmaceuticals CURNA $ 4,827 $ — $ — $ 4,827 OPKO Mexico 100 — (5 ) 95 OPKO Chile 5,283 — (243 ) 5,040 OPKO Health Europe 8,013 — (699 ) 7,314 FineTech 11,698 — — 11,698 SciVac 1,553 — 49 1,602 OPKO Renal 2,069 — — 2,069 OPKO Biologics 139,784 — — 139,784 EirGen Pharma Ltd — 66,823 (610 ) 66,213 Diagnostics OPKO Diagnostics 17,977 — — 17,977 OPKO Lab 32,988 — — 32,988 $ 224,292 $ 66,823 $ (1,508 ) $ 289,607

Acquisitions, Investments, and

Acquisitions, Investments, and Licenses	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
ACQUISITIONS, INVESTMENTS, AND LICENSES	ACQUISITIONS, INVESTMENTS AND LICENSES Pending Bio-Reference acquisition On June 3, 2015, we entered into an agreement and plan of merger pursuant to which we agreed to acquire Bio-Reference. Bio-Reference is the third largest full service clinical laboratory in the United States and is known for its innovative technological solutions and pioneering leadership in the areas of genomics and genetic sequencing. Under the terms of the merger agreement, which has been approved by the Boards of Directors of both companies, all holders of Bio-Reference common stock will receive 2.75 shares of OPKO common stock for each share of Bio-Reference common stock. Assuming a closing price of $16.74 per share of OPKO common stock, the transaction is valued at approximately $1.3 billion , or $46.04 per share of Bio-Reference common stock. We expect the transaction to be completed during the second half of 2015. Closing of the transaction is subject to approval of Bio-Reference’s shareholders and other customary conditions. Although we have entered into the merger agreement, there is no guarantee that the merger will be completed. EirGen Pharma Limited acquisition On May 5, 2015, we entered into a series of purchase agreements to acquire all of the issued and outstanding shares of EirGen, a specialty pharmaceutical company incorporated in Ireland focused on the development and commercial supply of high potency, high barrier to entry pharmaceutical products, for $133.8 million in the aggregate. We acquired the outstanding shares of EirGen for approximately $100.2 million in cash and delivered 2,420,487 shares of our Common Stock valued at approximately $33.6 million based on the closing price per share of our Common Stock as reported by the New York Stock Exchange on the closing date of the acquisition, $13.88 per share. The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of EirGen at the date of acquisition. The purchase price allocation for EirGen is preliminary: (In thousands) EirGen Current assets (1) $ 11,795 Intangible assets: IPR&D assets 19,597 Customer relationships 34,155 Currently marketed products 3,919 Total intangible assets 57,671 Goodwill 66,823 Property, plant and equipment 8,117 Other assets 1,232 Accounts payable and other liabilities (6,254 ) Deferred tax liability (5,618 ) Total purchase price $ 133,766 (1) Current assets include cash, accounts receivable, inventory and other assets of $5.5 million , $2.7 million , $2.2 million and $1.4 million , respectively, related to the EirGen acquisition. The fair value of the accounts receivable equals the gross contractual amount at the date of acquisition. Goodwill from the acquisition of EirGen principally relates to intangible assets that do not qualify for separate recognition (for instance, EirGen’s assembled workforce), our expectation to develop and market new products, and the deferred tax liability generated as a result of this being a partial stock transaction. Goodwill is not tax deductible for income tax purposes and was assigned to the pharmaceuticals segment. Revenue and Net loss in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2015 includes revenue and earnings (loss) of EirGen from the date of acquisition to June 30, 2015 of $2.3 million and $(0.8) million , respectively. Our IPR&D assets will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval, the IPR&D assets are then accounted for as finite-lived intangible assets and amortized on a straight-line basis over its estimated useful life. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, currently ranging from 3 to 20 years. We recognized $0.5 million of acquisition related costs for the acquisition of EirGen that were expensed in the current period as a component of Selling, general and administrative expense. Pro forma disclosure for EirGen acquisition The following table includes the pro forma results for the three and six months ended June 30, 2015 and 2014 of the combined companies as though the acquisition of EirGen had been completed as of the beginning of the period presented. For the three months ended June 30, For the six months ended June 30, (In thousands) 2015 2014 2015 2014 Revenues $43,848 $25,659 $76,769 $50,185 Net loss (43,420) (28,356) (162,331) (75,879) Net loss attributable to common shareholders (42,945) (27,759) (160,931) (74,742) Basic and diluted net loss per share $(0.09) $(0.07) $(0.35) $(0.18) The unaudited pro forma financial information is presented for information purposes only. The unaudited pro forma financial information may not necessarily reflect our future results of operations or what the results of operations would have been had we owned and operated EirGen as of the beginning of the period presented. Inspiro Medical Ltd. acquisition On April 17, 2014, we entered into a stock purchase agreement to acquire 100% of the issued and outstanding share capital of Inspiro Medical Ltd. (“Inspiro”), an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists and larger molecules to treat respiratory diseases. In connection with the transaction, we paid $1.5 million in cash and delivered 999,556 shares of our Common Stock valued at $8.6 million . Inspiro’s Inspiromatic™ is a “smart” easy-to-use dry powder inhaler with several advantages over existing devices. We anticipate that this innovative device will play a valuable role in the improvement of therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis and other respiratory diseases. We recorded the transaction as an asset acquisition and recorded the assets and liabilities at fair value. As the asset had no alternative future use, we recorded $10.1 million of acquired in-process research and development expenses. We record expense for in-process research and development projects accounted for as asset acquisitions which have not reached technological feasibility and which have no alternative future use. Investments The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2015 : (in thousands) Investment type Investment Carrying Value Underlying Equity in Net Assets Equity method investments $ 6,746 $ 23,735 Variable interest entity, equity method 903 — Available for sale investments 3,816 Warrants and options 9,969 Total carrying value of investments $ 21,434 Equity Method Investments Our equity method investments consist of investments in Pharmsynthez (ownership 17% ), Cocrystal Pharma, Inc. (“COCP”) ( 8% ), Sevion Therapeutics, Inc. (“Sevion”) ( 4% ), Non-Invasive Monitoring Systems, Inc. ( 1% ) and Neovasc ( 5% ). The total assets, liabilities, and net losses of our equity method investees as of and for the six months ended June 30, 2015 were $403.2 million , $(96.7) million , and $(52.5) million , respectively. We have determined that we and/or our related parties can significantly influence the success of our equity method investments through our board representation and voting power. Accordingly, we account for our investment in these entities under the equity method. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Loss from investments in investees in our Condensed Consolidated Statement of Operations. The aggregate value of our equity method investments based on the quoted market price of their common stock and the number of shares held by us as of June 30, 2015 is $88.1 million . See further discussion of our investment in Pharmsynthez below. Available for Sale Investments Our available for sale investments consist of investments in RXi Pharmaceuticals Corporation (“RXi”) (ownership 10% ), ChromaDex Corporation ( 2% ) and ARNO Therapeutics, Inc. (“ARNO”) ( 4% ). We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of our available for sale investments. Accordingly, we account for our investment in these entities as available for sale, and we record changes in these investments as an unrealized gain or loss in Other comprehensive income (loss) each reporting period. Sales of Investments Gains (losses) included in earnings from sales of our investments for the six months ended June 30, 2014 were $1.3 million and were recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations. We did not have any such activity in the six months ended June 30, 2015 . The cost of securities sold is based on the specific identification method. Warrants and Options In addition to our equity method investments and available for sale investments, we hold options to purchase 1.0 million additional shares of Neovasc, which are fully vested as of December 31, 2014, and 1.0 million , 0.8 million , 0.1 million and 1.7 million of warrants to purchase additional shares of COCP, ARNO, Sevion and MabVax Therapeutics Holdings, Inc., respectively. We recorded the changes in the fair value of the options and warrants in Fair value changes of derivative instruments, net in our Consolidated Statements of Operations. We record the fair value of the options and warrants in Investments, net in our Consolidated Balance Sheets. See further discussion of the Company’s options and warrants in Note 8 and Note 9. Pharmsynthez transactions In April 2013, we entered into a series of concurrent transactions with Pharmsynthez, a Russian pharmaceutical company traded on the Moscow Stock Exchange. The transactions consisted of: • We delivered approximately $9.6 million in cash to Pharmsynthez. • Pharmsynthez issued to us approximately 13.6 million of its common shares. • Pharmsynthez agreed, at its option, to issue approximately 12.0 million common shares to us or to pay us cash in Russian Rubles (“RUR”) 265.0 million ( $8.1 million at December 31, 2013) on or before December 31, 2013 (the “Pharmsynthez Note Receivable”). In January 2014, Pharmsynthez delivered to us approximately 12.0 million shares of its common stock in satisfaction of the Pharmsynthez Notes Receivable. • We had a right to purchase additional shares in Pharmsynthez at a fixed price if Pharmsynthez paid us in cash rather than delivering to us the 12.0 million Pharmsynthez common shares (the “Purchase Option”), however in connection with the settlement of the Pharmsynthez Note Receivable in January 2014, this right terminated. • We granted rights to certain technologies in the Russian Federation, Ukraine, Belarus, Azerbaijan and Kazakhstan (the “Territories”) to Pharmsynthez. • We will receive from Pharmsynthez royalties on net sales of products incorporating the technologies in the Territories, as well as a percentage of any sublicense income from third parties for the technologies in the Territories. • Pharmsynthez paid us $9.5 million under the various collaboration and funding agreements for the grant of rights and development of the technologies (the “Collaboration Payments”). We recorded the shares received in Pharmsynthez as an equity method investment. We initially recorded the Pharmsynthez Note Receivable, and the Purchase Option, as financial instruments and elected the fair value option for subsequent measurement. Changes in the fair value of the Pharmsynthez Note Receivable and the Purchase Option were recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. Upon settlement in January 2014, we recorded the additional shares at fair value as an equity method investment. We have accounted for the license and development activities as a multi-element arrangement, and allocated the total arrangement consideration based on the relative selling prices of the elements. We record the allocated consideration for development activities as an offset to Research and development expenses over the three -year term of the Collaboration Payments. We recorded revenue in connection with the grant of rights to the technologies proportionately as the payments were received. During the six months ended June 30, 2015 and 2014, we recorded $0 million and $0.5 million , respectively, in Revenue from transfer of intellectual property and $0.5 million and $0.8 million , respectively, as an offset to Research and development expenses related to the Collaboration Payments. Investments in variable interest entities We have determined that we hold variable interests in SciVac and Zebra Biologics, Inc. (“Zebra”). We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support. We own 840,000 shares of Zebra Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 28% at June 30, 2015 ). Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a member of our Board of Directors, is a founder of Zebra and, along with Dr. Frost, serves as a member of Zebra’s Board of Directors. In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related party group’s investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. We determined that we do not have the power to direct the activities that most significantly impact Zebra’s economic performance. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra’s economic performance. We did determine, however, that we can significantly influence the success of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebra’s operations and account for our investment in Zebra under the equity method. Consolidated variable interest entities In June 2012, we acquired a 50% stock ownership in SciVac ( 45% as of June 30, 2015 ) from FDS Pharma LLP (“FDS”). SciVac is a privately-held Israeli company that produces a third-generation hepatitis B-vaccine. From November 2012 until June 30, 2015 , we loaned to SciVac a combined $7.6 million for working capital purposes. We have determined that we hold variable interests in SciVac based on our assessment that SciVac does not have sufficient resources to carry out its principal activities without financial support. In order to determine the fair market value of our investment in SciVac, we have utilized a business enterprise valuation approach. In order to determine the primary beneficiary of SciVac, we evaluated our investment to identify if we had the power to direct the activities that most significantly impact the economic performance of SciVac. We have determined that the power to direct the activities that most significantly impact the economic performance of SciVac is conveyed through SciVac’s board of directors. SciVac’s board of directors appoint and oversee SciVac’s management team who carry out the activities that most significantly impact the economic performance of SciVac. As part of the share and debt purchase agreement, SciVac’s board of directors is constituted by 5 members, of which 3 members are appointed by us, representing 60% of SciVac’s board. Based on this analysis, we determined that we have the power to direct the activities of SciVac and as such we are the primary beneficiary. As a result of this conclusion, we have consolidated the results of operations and financial position of SciVac and recorded a reduction of equity for the portion of SciVac we do not own. The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of June 30, 2015 and December 31, 2014. These assets are owned by, and these liabilities are obligations of, SciVac, not us. (In thousands) June 30, December 31, 2014 Assets Current assets: Cash and cash equivalents $ 21 $ 393 Accounts receivable, net 304 316 Inventories, net 1,433 1,649 Prepaid expenses and other current assets 774 718 Total current assets 2,532 3,076 Property, plant and equipment, net 1,791 1,725 Intangible assets, net 843 875 Goodwill 1,602 1,553 Other assets 368 384 Total assets $ 7,136 $ 7,613 Liabilities Current liabilities: Accounts payable $ 900 $ 445 Accrued expenses 4,476 4,446 Notes payable 5,409 5,189 Total current liabilities 10,785 10,080 Other long-term liabilities 1,884 2,042 Total liabilities $ 12,669 $ 12,122 In March 2015, SciVac entered into an agreement pursuant to which Levon Resources Ltd. ("Levon") agreed to acquire 100% of the issued and outstanding ordinary shares of SciVac by way of a court-approved plan of arrangement (the "Arrangement"). Upon closing, which occurred in July 2015, Levon changed its name to SciVac Therapeutics Inc. ("New SciVac"), and the officers and directors of SciVac became officers and directors of New SciVac. The former owners of SciVac now hold 68.4% of the outstanding shares of New SciVac, resulting in our ownership interest of approximately 24.5% .

Debt

Debt	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
DEBT	DEBT In January 2013, we entered into note purchase agreements (the “2033 Senior Notes”) with qualified institutional buyers and accredited investors (collectively the “Purchaser”) in a private placement in reliance on exemptions from registration under the Securities Act of 1933, (the “Securities Act”). The Purchasers of the 2033 Senior Notes include Frost Gamma Investments Trust, a trust affiliated with Dr. Frost, and Hsu Gamma Investment, L.P., an entity affiliated with Dr. Jane H. Hsiao, our Vice Chairman and Chief Technology Officer. The 2033 Senior Notes were issued on January 30, 2013 . The 2033 Senior Notes, which total $175.0 million , bear interest at the rate of 3.00% per year, payable semiannually on February 1 and August 1 of each year, beginning August 1, 2013. The 2033 Senior Notes will mature on February 1, 2033 , unless earlier repurchased, redeemed or converted. Upon a fundamental change as defined in the instruments governing the 2033 Senior Notes, subject to certain exceptions, the holders may require us to repurchase all or any portion of their 2033 Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the 2033 Senior Notes being repurchased, plus any accrued and unpaid interest to but not including the fundamental change repurchase date. The following table sets forth information related to the 2033 Senior Notes which is included our Condensed Consolidated Balance Sheets as of June 30, 2015 : (In thousands) Embedded conversion option 2033 Senior Notes Discount Total Balance at December 31, 2014 $ 65,947 $ 87,642 $ (22,135 ) $ 131,454 Amortization of debt discount — — 1,680 1,680 Change in fair value of embedded derivative 67,950 — — 67,950 Conversion (60,346 ) (41,442 ) 9,907 (91,881 ) Balance at June 30, 2015 $ 73,551 $ 46,200 $ (10,548 ) $ 109,203 The 2033 Senior Notes will be convertible at any time on or after November 1, 2032, through the second scheduled trading day immediately preceding the maturity date, at the option of the holders. Additionally, holders may convert their 2033 Senior Notes prior to the close of business on the scheduled trading day immediately preceding November 1, 2032, under the following circumstances: (1) conversion based upon satisfaction of the trading price condition relating to the 2033 Senior Notes; (2) conversion based on the Common Stock price; (3) conversion based upon the occurrence of specified corporate events; or (4) if we call the 2033 Senior Notes for redemption. The 2033 Senior Notes will be convertible into cash, shares of our Common Stock, or a combination of cash and shares of Common Stock, at our election unless we have made an irrevocable election of net share settlement. The initial conversion rate for the 2033 Senior Notes will be 141.48 shares of Common Stock per $1,000 principal amount of 2033 Senior Notes (equivalent to an initial conversion price of approximately $7.07 per share of Common Stock), and will be subject to adjustment upon the occurrence of certain events. In addition, we will, in certain circumstances, increase the conversion rate for holders who convert their 2033 Senior Notes in connection with a make-whole fundamental change (as defined in the Indenture) and holders who convert upon the occurrence of certain specific events prior to February 1, 2017 (other than in connection with a make-whole fundamental change). Holders of the 2033 Senior Notes may require us to repurchase the 2033 Senior Notes for 100% of their principal amount, plus accrued and unpaid interest, on February 1, 2019, February 1, 2023 and February 1, 2028, or following the occurrence of a fundamental change as defined in the indenture governing the 2033 Senior Notes. See further discussion in Note 14. We may not redeem the 2033 Senior Notes prior to February 1, 2017. On or after February 1, 2017 and before February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes but only if the last reported sale price of our Common Stock exceeds 130% of the applicable conversion price for at least 20 trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date on which we deliver the redemption notice. The redemption price will equal 100% of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest to but not including the redemption date. On or after February 1, 2019, we may redeem for cash any or all of the 2033 Senior Notes at a redemption price of 100% of the principal amount of the 2033 Senior Notes to be redeemed, plus any accrued and unpaid interest up to but not including the redemption date. The terms of the 2033 Senior Notes, include, among others: (i) rights to convert into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the 2033 Senior Notes on or after February 1, 2017 but prior to February 1, 2019. We have determined that these specific terms are considered to be embedded derivatives. As a result, embedded derivatives are required to be separated from the host contract, the 2033 Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. We have concluded that the embedded derivatives within the 2033 Senior Notes meet these criteria and, as such, must be valued separate and apart from the 2033 Senior Notes and recorded at fair value each reporting period. For accounting and financial reporting purposes, we combine these embedded derivatives and value them together as one unit of accounting. At each reporting period, we record these embedded derivatives at fair value which is included as a component of the 2033 Senior Notes on our Condensed Consolidated Balance Sheets. On August 30, 2013, one of the conversion rights in the 2033 Senior Notes was triggered. Holders of the 2033 Senior Notes converted $16.9 million principal amount into 2,396,145 shares of our Common Stock at a rate of 141.4827 shares of Common Stock per $1,000 principal amount of 2033 Senior Notes. In June 2014, we entered into an exchange agreement with a holder of the Company’s 2033 Senior Notes pursuant to which such holder exchanged $70.4 million in aggregate principal amount of 2033 Senior Notes for 10,974,431 shares of the Company’s Common Stock and approximately $0.8 million in cash representing accrued interest through the date of completion of the exchange. In March 2015, we entered into exchange agreements with certain holders of our 2033 Senior Notes pursuant to which such holders exchanged $36.4 million in aggregate principal amount of 2033 Senior Notes for 5,363,896 shares of the Company’s Common Stock and approximately $0.2 million in cash representing accrued interest through the date of completion of the exchange. We recorded a $0.3 million non-cash loss related to the exchange. The loss on exchange is included within Other income (expense) in our Condensed Consolidated Statement of Operations. On April 1, 2015, we announced that our 2033 Senior Notes are convertible by holders of such notes. We have elected to satisfy our conversion obligation under the 2033 Senior Notes in shares of our Common Stock. This conversion right was triggered because the closing price per share of our Common Stock has exceeded $9.19 , or 130% of the initial conversion price of $7.07 , for at least 20 of 30 consecutive trading days during the period ending on March 31, 2015. The 2033 Senior Notes were convertible until June 30, 2015, and may be convertible thereafter, if one or more of the conversion conditions specified in the Indenture, dated as of January 30, 2013, by and between the Company and Wells Fargo Bank N.A., is satisfied during future measurement periods. Refer to Note 14. Pursuant to the Indenture, a holder who elects to convert the 2033 Senior Notes will receive 141.4827 shares of our Common Stock plus such number of additional shares as is applicable on the conversion date per $1,000 principal amount of 2033 Senior Notes based on the early conversion provisions in the Indenture. In May 2015, pursuant to the conversion right, a holder of our 2033 Senior Notes converted $5.0 million in aggregate principal amount of 2033 Senior Notes for 726,036 shares of the Company’s Common Stock. We recorded a $30,000 non-cash gain related to the exchange. The gain on exchange is included within Other income (expense) in our Condensed Consolidated Statement of Operations. We used a binomial lattice model in order to estimate the fair value of the embedded derivative in the 2033 Senior Notes. A binomial lattice model generates two probable outcomes — one up and another down —arising at each point in time, starting from the date of valuation until the maturity date. A lattice model was initially used to determine if the 2033 Senior Notes would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the 2033 Senior Notes will be converted early if the conversion value is greater than the holding value; or (ii) the 2033 Senior Notes will be called if the holding value is greater than both (a) the redemption price (as defined in the Indenture) and (b) the conversion value plus the coupon make-whole payment at the time. If the 2033 Senior Notes are called, then the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the 2033 Senior Notes. Using this lattice model, we valued the embedded derivatives using the “with-and-without method,” where the value of the 2033 Senior Notes including the embedded derivatives is defined as the “with,” and the value of the 2033 Senior Notes excluding the embedded derivatives is defined as the “without.” This method estimates the value of the embedded derivatives by looking at the difference in the values between the 2033 Senior Notes with the embedded derivatives and the value of the 2033 Senior Notes without the embedded derivatives. The lattice model requires the following inputs: (i) price of our Common Stock; (ii) Conversion Rate (as defined in the Indenture); (iii) Conversion Price (as defined in the Indenture); (iv) maturity date; (v) risk-free interest rate; (vi) estimated stock volatility; and (vii) estimated credit spread for the Company. The following table sets forth the inputs to the lattice model used to value the embedded derivative: June 30, 2015 Stock price $16.08 Conversion Rate 141.4827 Conversion Price $7.07 Maturity date February 1, 2033 Risk-free interest rate 1.19% Estimated stock volatility 41% Estimated credit spread 1,133 basis points The following table sets forth the fair value of the 2033 Senior Notes with and without the embedded derivatives, and the fair value of the embedded derivatives at June 30, 2015 . At June 30, 2015 the principal amount of the 2033 Senior Notes was $46.2 million : (In thousands) June 30, 2015 Fair value of 2033 Senior Notes: With the embedded derivatives $ 107,743 Without the embedded derivatives $ 34,192 Estimated fair value of the embedded derivatives $ 73,551 Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the embedded derivatives. For example, a decrease in our estimated credit spread results in an increase in the estimated value of the embedded derivatives. Conversely, a decrease in the price of our Common Stock results in a decrease in the estimated fair value of the embedded derivatives. For the six months ended June 30, 2015 , we observed an increase in the market price of our Common Stock which resulted in a $68.0 million increase in the estimated fair value of our embedded derivatives recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. We have line of credit agreements with eight financial institutions as of June 30, 2015 and twelve financial institutions as of December 31, 2014 in Chile and Spain. These lines of credit are used primarily as a source of working capital for inventory purchases. The following table summarizes the amounts outstanding under the Chilean and Spanish lines of credit: (Dollars in thousands) Balance Outstanding Lender Interest rate on borrowings at June 30, 2015 Credit line capacity June 30, December 31, 2014 Itau Bank 6.00% $1,800 $1,171 $965 Bank of Chile 5.50% 2,250 1,572 1,410 BICE Bank 6.16% 2,300 1,088 1,249 BBVA Bank 5.00% 2,300 1,552 795 Penta Bank 7.58% 1,200 631 1,008 Security Bank 6.16% 940 305 361 Estado Bank 5.30% 2,800 2,039 1,870 BBVA Bank 4.75% 277 — — Total $13,867 $8,358 $7,658 At June 30, 2015 and December 31, 2014 , the weighted average interest rate on our lines of credit was approximately 5.7% and 6.1% , respectively. At June 30, 2015 and December 31, 2014 , we had mortgage notes and other debt related to OPKO Health Europe and EirGen as follows: (In thousands) June 30, December 31, 2014 Current portion of notes payable $ 832 $ 608 Other long-term liabilities 2,393 2,435 Total mortgage notes and other debt $ 3,225 $ 3,043 The mortgages and other debts mature at various dates ranging from 2015 through 2024 bearing variable interest rates from 2.7% up to 6.3% . The weighted average interest rate on the mortgage notes and other debt at June 30, 2015 and December 31, 2014 , was 3.2% and 3.4% , respectively. The mortgages are secured by our office space in Barcelona.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) For the six months ended June 30, 2015 , changes in Accumulated other comprehensive income (loss), net of tax, were as follows: (In thousands) Foreign currency Unrealized gain (loss) in Accumulated OCI Total Balance at December 31, 2014 $ (6,717 ) $ (5,675 ) $ (12,392 ) Other comprehensive income before reclassifications, net of tax (4,547 ) (1,941 ) (6,488 ) Amounts reclassified from accumulated other comprehensive income, net of tax — — — Net other comprehensive loss (4,547 ) (1,941 ) (6,488 ) Balance at June 30, 2015 $ (11,264 ) $ (7,616 ) $ (18,880 )

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. A summary of our investments classified as available for sale and carried at fair value, is as follows: As of June 30, 2015 (In thousands) Amortized Cost Gross unrealized gains in Accumulated OCI Gross unrealized losses in Accumulated OCI Gain/(Loss) in Accumulated Deficit Fair value Common stock investments, available for sale $ 11,479 $ 898 $ (7,119 ) $ (1,442 ) $ 3,816 Common stock options/warrants 3,925 — — 6,044 9,969 Total assets $ 15,404 $ 898 $ (7,119 ) $ 4,602 $ 13,785 As of December 31, 2014 (In thousands) Amortized Cost Gross unrealized gains in Accumulated OCI Gross unrealized losses in Accumulated OCI Gain/(Loss) in Accumulated Deficit Fair value Common stock investments, available for sale $ 11,479 $ 293 $ (4,573 ) $ (1,441 ) $ 5,758 Common stock options/warrants 1,425 216 — 4,673 6,314 Total assets $ 12,904 $ 509 $ (4,573 ) $ 3,232 $ 12,072 Any future fluctuation in fair value related to our available for sale investments that is judged to be temporary, and any recoveries of previous write-downs, will be recorded in Accumulated other comprehensive income or loss. If we determine that any future valuation adjustment was other-than-temporary, we will record a loss during the period such determination is made. Any future changes in the fair value of option and warrant instruments will be recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. As of June 30, 2015 , we have money market funds that qualify as cash equivalents, forward contracts for inventory purchases (Refer to Note 9) and contingent consideration related to the acquisitions of CURNA, OPKO Diagnostics, OPKO Health Europe, and OPKO Renal that are required to be measured at fair value on a recurring basis. In addition, in connection with our investment and our consulting agreement with Neovasc, we record the related Neovasc options at fair value as well as the warrants from COCP, ARNO, Sevion and MabVax. Our financial assets and liabilities measured at fair value on a recurring basis are as follows: Fair value measurements as of June 30, 2015 (In thousands) Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Money market funds $ 52,563 $ — $ — $ 52,563 Common stock investments, available for sale 3,816 — — 3,816 Common stock options/warrants — 9,969 — 9,969 Forward contracts — 115 — 115 Total assets $ 56,379 $ 10,084 $ — $ 66,463 Liabilities: Embedded conversion option $ — $ — $ 73,551 $ 73,551 Contingent consideration: CURNA — — 433 433 OPKO Diagnostics — — 13,342 13,342 OPKO Renal — — 60,090 60,090 OPKO Health Europe — — 464 464 Total liabilities $ — $ — $ 147,880 $ 147,880 Fair value measurements as of December 31, 2014 (In thousands) Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Money market funds $ 71,286 $ — $ — $ 71,286 Common stock investments, available for sale 5,758 — — 5,758 Common stock options/warrants — 6,314 — 6,314 Forward contracts — 36 — 36 Total assets $ 77,044 $ 6,350 $ — $ 83,394 Liabilities: Embedded conversion option $ — $ — $ 65,947 $ 65,947 Contingent consideration: CURNA — — 440 440 OPKO Diagnostics — — 13,578 13,578 OPKO Renal — — 55,780 55,780 OPKO Health Europe — — 1,769 1,769 Total liabilities $ — $ — $ 137,514 $ 137,514 The carrying amount and estimated fair value of our long-term debt, as well as the applicable fair value hierarchy tiers, are contained in the table below. The fair value of the 2033 Senior Notes is determined using a binomial lattice approach in order to estimate the fair value of the embedded derivative in the 2033 Senior Notes. Refer to Note 6. June 30, 2015 (In thousands) Carrying Value Total Fair Value Level 1 Level 2 Level 3 2033 Senior Notes $ 35,652 $ 34,192 $ — $ — $ 34,192 There have been no transfers between Level 1 and Level 2 and no transfers to or from Level 3 of the fair value hierarchy. As of June 30, 2015 and December 31, 2014 , the carrying value of our other assets and liabilities approximates their fair value due to their short-term nature. The following tables reconcile the beginning and ending balances of our Level 3 assets and liabilities as of June 30, 2015 : June 30, 2015 (In thousands) Contingent consideration Embedded conversion option Balance at December 31, 2014 $ 71,567 $ 65,947 Total losses (gains) for the period: Included in results of operations 4,836 67,950 Foreign currency impact (261 ) — Payments (1,813 ) — Conversion — (60,346 ) Balance at June 30, 2015 $ 74,329 $ 73,551 The estimated fair values of our financial instruments have been determined by using available market information and what we believe to be appropriate valuation methodologies. We use the following methods and assumptions in estimating fair value: Contingent consideration – We estimate the fair value of the contingent consideration utilizing a discounted cash flow model for the expected payments based on estimated timing and expected revenues. We use several discount rates depending on each type of contingent consideration related to OPKO Diagnostics, CURNA, OPKO Health Europe and OPKO Renal transactions. The discount rates used range from 6% to 27% and were based on the weighted average cost of capital for those businesses. If the discount rates were to increase by 1% , on each transaction, the contingent consideration would decrease by $1.2 million . If estimated future sales were to decrease by 10% , the contingent consideration related to OPKO Renal would decrease by $1.7 million . As of June 30, 2015 , of the $74.3 million of contingent consideration, $41.1 million is recorded in Accrued expenses and $33.2 million is recorded in Other long-term liabilities. As of December 31, 2014 , of the $71.6 million of contingent consideration, $27.4 million is recorded in Accrued expenses and $44.2 million is recorded in Other long-term liabilities. Deferred payments – We estimate the fair value of the deferred payments utilizing a discounted cash flow model for the expected payments. Embedded conversion option – We estimate the fair value of the embedded conversion option related to the 2033 Senior Notes using a binomial lattice model. Refer to Note 6 for detail description of the binomial lattice model and the fair value assumptions used.

Derivative Contracts

Derivative Contracts	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE CONTRACTS	DERIVATIVE CONTRACTS The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets: (In thousands) Balance Sheet Component June 30, December 31, Derivative financial instruments: Common Stock options/warrants Investments, net $ 9,969 $ 6,314 Embedded conversion option 2033 Senior Notes, net of discount and estimated fair value of embedded derivatives $ 73,551 $ 65,947 Forward contracts Unrealized gains on forward contracts are recorded in Prepaid expenses and other current assets. Unrealized losses on forward contracts are recorded in Accrued expenses. $ 115 $ 36 We enter into foreign currency forward exchange contracts to cover the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit. Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date. To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At June 30, 2015 and December 31, 2014 , our derivative financial instruments do not meet the documentation requirements to be designated as hedges. Accordingly, we recognize the changes in Fair value of derivative instruments, net in our Condensed Consolidated Statements of Operations. The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2015 and 2014: Three months ended June 30, Six months ended June 30, (In thousands) 2015 2014 2015 2014 Derivative gain (loss): Common Stock options/warrants (1) $ (2,446 ) $ (860 ) $ 1,425 $ (263 ) 2033 Senior Notes (14,220 ) 11,882 (67,950 ) 770 Forward contracts 110 (55 ) 181 87 Total $ (16,556 ) $ 10,967 $ (66,344 ) $ 594 (1) Amount for 2014 includes the Pharmsynthez Note Receivable and the Purchase Option. The outstanding forward contracts at June 30, 2015 and December 31, 2014 , have been recorded at fair value, and their maturity details are as follows: (In thousands) Days until maturity Contract value Fair value at June 30, 2015 Effect on income (loss) 0 to 30 $ 1,414 $ 1,466 $ 52 31 to 60 324 336 12 61 to 90 939 981 42 91 to 120 180 188 8 More than 120 31 32 1 Total $ 2,888 $ 3,003 $ 115 (In thousands) Days until maturity Contract value Fair value at December 31, 2014 Effect on income (loss) 0 to 30 $ 750 $ 780 $ 30 31 to 60 90 93 3 61 to 90 — — — 91 to 120 68 71 3 121 to 180 — — — More than 180 — — — Total $ 908 $ 944 $ 36

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS In April 2015, we made a $2.5 million investment in a private placement transaction with MabVax Therapeutics Holdings, Inc. pursuant to which we acquired 33,333 shares of MabVax Series E Convertible Preferred Stock and warrants to purchase 1,666,667 shares of MabVax common stock. Prior to our investment in MabVax, Dr. Frost held shares in MabVax indirectly through an entity in which he has an ownership interest. Dr. Frost, as well as non-affiliated investors, invested in the private placement transaction on the same financial terms. In connection with the OPKO investment, Steven Rubin, our Executive Vice President, Administration, was appointed as an advisor to MabVax, and we have the right to designate two board members. In February 2014, Dr. Frost, our Chairman and Chief Executive Officer, paid a filing fee of $280,000 to the Federal Trade Commission (the "FTC") under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) in connection with filings made by us and Dr. Frost. We reimbursed Dr. Frost for the HSR filing fee. In August 2013, we acquired OPKO Biologics (formerly PROLOR) pursuant to an Agreement and Plan of Merger dated as of April 23, 2013 in an all-stock transaction. Until completion of the acquisition, Dr. Frost was PROLOR’s Chairman of the Board and a greater than 5% stockholder of PROLOR. Dr. Hsiao and Mr. Rubin were also directors and less than 5% stockholders of PROLOR. In January 2013, we sold $175.0 million aggregate principal amount of 2033 Senior Notes in a private placement in reliance on exemptions from registration under the Securities Act. The Purchasers of the 2033 Senior Notes include the Gamma Trust and Hsu Gamma. The 2033 Senior Notes were issued on January 30, 2013. During the six months ended June 30, 2014 , FineTech recorded revenue of $0.3 million , respectively, for the sale of APIs to Teva Pharmaceutical Industries, Limited (“Teva”). Dr. Frost previously served as the Chairman of the Board of Directors of Teva until 2015. No revenue was recorded for the six months ended June 30, 2015 . In 2012, we made a $1.7 million investment in Biozone. Effective January 2, 2014, Biozone completed a merger with Cocrystal Discovery, Inc. (“Cocrystal”), another entity in which we had an equity investment. The name of the issuer was changed to Cocrystal Pharma, Inc. ("COCP"). Dr. Frost previously invested in both Biozone and Cocrystal. Effective January 16, 2014, we invested an additional $0.5 million in the company as part of a $2.75 million private placement and received 1.0 million shares of common stock and 1.0 million 10 -year warrants exercisable at $0.50 per share. At June 30, 2015 , we hold an 8% ownership interest in COCP. We hold investments in Zebra (ownership 28% ), Sevion ( 4% ), Neovasc ( 5% ), ChromaDex Corporation ( 2% ) and ARNO ( 4% ). The acquisition of these investments were considered related party transactions as a result of our executive management’s ownership interests and/or board representation in these entities. See further discussion of our investments in Note 5. In May 2015, we agreed to make an additional $500 thousand investment in Sevion as part of a private placement transaction completed in the third quarter. We lease office space from Frost Real Estate Holdings, LLC (“Frost Holdings”) in Miami, Florida, where our principal executive offices are located. Effective May 28, 2015, we entered into an amendment to our lease agreement with Frost Holdings. The lease, as amended, is for approximately 25,000 square feet of space. The lease provides for payments of approximately $66 thousand per month in the first year increasing annually to $75 thousand per month in the fifth year, plus applicable sales tax. The rent is inclusive of operating expenses, property taxes and parking. The rent was reduced by $216 thousand for the cost of tenant improvements. We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr. Frost. Prior to 2015, we reimbursed Dr. Frost in an amount equal to the cost of a first class airline ticket between the travel cities for each executive, including Dr. Frost, traveling on the airplane for Company-related business. Beginning in the first quarter of 2015, we reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business. We do not reimburse Dr. Frost for personal use of the airplane by Dr. Frost or any other executive. For the three and six months ended June 30, 2015 , we recognized approximately $167 thousand and $293 thousand , respectively, for Company-related travel by Dr. Frost and other OPKO executives. For the three and six months ended June 30, 2014 , we reimbursed Dr. Frost approximately $49 thousand and $62 thousand , respectively, for Company-related travel by Dr. Frost and other OPKO executives.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In connection with our acquisitions of CURNA, OPKO Diagnostics, OPKO Health Europe, and OPKO Renal, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result, as of June 30, 2015 , we recorded $74.3 million as contingent consideration, with $41.1 million recorded within Accrued expenses and $33.2 million recorded within Other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Refer to Note 4. In addition, in connection with our asset purchase agreement with Schering Plough Corporation, now Merck & Co. (“Merck”), we are required to pay up to an additional $25.0 million upon the achievement of certain development milestones. Future payments to be made under the agreement with Merck will be recognized when the milestones are achieved and consideration is issued or becomes issuable. Refer to Note 12. In July 2012, OPKO Lab received a letter from AdvanceMed Corporation (“AdvanceMed”) regarding a post-payment review conducted by AdvanceMed (the “Post-Payment Review Letter”). The Post-Payment Review Letter originated with a post payment review audit by AdvanceMed of 183 claims submitted by OPKO Lab to the Medicare program. OPKO Lab believes that its billing practices were appropriate and it is following the appeal process set forth by Medicare. OPKO Lab received a partially favorable determination, which reduced the amount of the alleged overpayment, and it continues to appeal the remaining alleged overpayments. No assurances can be given about the outcome of the appeal. On or around October 21, 2014, we received a Civil Investigative Demand (“Demand”) from the U.S. Attorney’s Office for the Middle District of Tennessee (“Attorney’s Office”). The Demand concerns an investigation of allegations that the Company or one of its affiliated entities or other parties submitted false claims for payment related to services provided to government healthcare program beneficiaries in violation of the False Claims Act, 31 U.S.C. Section 3729. We intend to fully cooperate with the investigation and produce documents responsive to the Demand. It is too early to assess the probability of a favorable or unfavorable outcome in this matter or the loss or range of loss, if any. Following the announcement of entry into an agreement and plan of merger with Bio-Reference, four putative class action complaints challenging the merger were filed in the Superior Court of New Jersey in Bergen County. Two of the complaints were filed in the Law Division, and two of the complaints were filed in the Chancery Division. The complaints are captioned: Naik v. Bio-Reference Laboratories, Inc. , et al., Docket No. C-180-15 filed in the Chancery Division on June 11, 2015; Katcher v. Bio-Reference Laboratories, Inc., et al ., Docket No. C-207-15 filed in the Chancery Division on July 16, 2015; Cohen v. Bio-Reference Laboratories, Inc., et a l., Docket No. L-5697-15 filed in the Law Division on June 18, 2015; and Ertan v. Bio-Reference Laboratories, Inc., et al ., Docket No. L-5701-15 filed in the Law Division on June 18, 2015. The complaints name Bio-Reference, OPKO, a wholly-owned merger subsidiary of OPKO (“Merger Sub”) and members of the Bio-Reference board as defendants. The complaints generally allege, among other things, that members of the Bio-Reference board breached their fiduciary duties to Bio-Reference’s shareholders by agreeing to sell Bio-Reference for an inadequate price and agreeing to inappropriate deal protection provisions in the merger agreement that may preclude Bio-Reference from soliciting any potential acquirers and limit the ability of the Bio-Reference board to act with respect to investigating and pursuing superior proposals and alternatives. The complaints also allege that Bio-Reference, OPKO and Merger Sub have aided and abetted the Bio-Reference board members’ breaches of their fiduciary duties. The complaints seek injunctive relief enjoining Bio-Reference and OPKO from consummating the merger at the agreed upon price unless and/or until the defendants cure their breaches of fiduciary duty (or, in the event the merger is consummated, rescinding the merger or awarding rescissory damages). The complaints also seek to recover costs and disbursement from the defendants, including attorneys’ fees and experts’ fees. After the complaints were filed, on July 24, 2015, the parties executed a stipulated consent order that the actions would be consolidated for all purposes, including trial, in the Chancery Division under Docket No. C-207-15, bearing the caption In re Bio-Reference Laboratories, Inc. Shareholder Litigation. The Company denies the allegations and intends to defend the actions. It is too early to assess the probability of a favorable or unfavorable outcome or the loss or range of loss, if any. Under a license agreement one of our subsidiaries has with Washington University in St. Louis, we are obligated to pay Washington University a single digit percentage of any sublicensing payment we receive in connection with a sublicense of our rights to the Washington University patents subject to certain exceptions. In connection with the Pfizer Transaction, we sublicensed to Pfizer the patents licensed to us by Washington University and paid to Washington University the sublicensing payment we believe is due under the license agreement. Washington University has questioned the computation of the sublicense payment and has notified us that it would like to review additional information relating to the sublicense and the Pfizer Transaction to determine whether additional amounts are owed to it. We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review these accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For the matters referenced in the paragraph below, the amount of liability is not probable or the amount cannot be reasonably estimated; and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for matters which the likelihood of material loss is at least reasonably possible, we provide disclosure of the possible loss or range of loss; however, if a reasonable estimate cannot be made, we will provide disclosure to that effect. We are a party to other litigation in the ordinary course of business. We do not believe that any such litigation will have a material adverse effect on our business, financial condition, results of operations or cash flows. We expect to incur substantial losses as we continue the development of our product candidates, continue our other research and development activities, and establish a sales and marketing infrastructure in anticipation of the commercialization of our diagnostic and pharmaceutical product candidates. We currently have limited commercialization capabilities, and it is possible that we may never successfully commercialize any of our diagnostic and pharmaceutical product candidates. We do not currently generate significant revenue from any of our diagnostic and pharmaceutical product candidates. Our research and development activities are budgeted to expand over a period of time and will require further resources if we are to be successful. As a result, we believe that our operating losses are likely to be substantial over the next several years. We may need to obtain additional funds to further develop our research and development programs, and there can be no assurance that additional capital will be available to us on acceptable terms, or at all. At June 30, 2015 , we were committed to make future purchases for inventory and other items that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating $19.2 million .

Strategic Alliances

Strategic Alliances	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
STRATEGIC ALLIANCES	STRATEGIC ALLIANCES Pfizer Inc. We plan to develop a portfolio of product candidates through a combination of internal development and external partnerships. In December 2014, we entered into an exclusive worldwide agreement with Pfizer Inc. (“Pfizer”) for the development and commercialization of our long-acting hGH-CTP for the treatment of growth hormone deficiency (“GHD”) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (“SGA”) (the “Pfizer Transaction”). The Pfizer Transaction closed in January 2015 following the termination of the waiting period under the Hart-Scott-Rodino Act. Under the terms of the Pfizer Transaction, we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize hGH-CTP worldwide. In addition, we are eligible to receive initial tiered royalty payments associated with the commercialization of hGH-CTP for Adult GHD with percentage rates ranging from the high teens to mid-twenties. Upon the launch of hGH-CTP for Pediatric GHD in certain major markets, the royalties will transition to regional, tiered gross profit sharing for both hGH-CTP and Pfizer’s Genotropin®. The agreement with Pfizer will remain in effect until the last sale of the licensed product, unless earlier terminated as permitted under the agreement. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Agreement is terminated by us for Pfizer’s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions. We will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA. Pfizer will be responsible for all development costs for additional indications as well as all post-marketing studies. In addition, Pfizer will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan. For revenue recognition purposes, we viewed the Pfizer Transaction as a multiple-element arrangement. Multiple-element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. We evaluated whether the delivered element under the arrangement has standalone value and qualifies for treatment as a separate unit of accounting. Deliverables that do not meet these criteria are not evaluated separately for the purpose of revenue recognition. For a single unit of accounting, payments received are recognized in a manner consistent with the final deliverable. We determined that the deliverables under the Pfizer Transaction, including the licenses granted to Pfizer, as well as our obligations to provide various research and development services, will be accounted for as a single unit of account. This determination was made because the ongoing research and development services to be provided by us are essential to the overall arrangement as we have significant knowledge and technical know-how that is important to realizing the value of the licenses granted. The performance period over which the revenue will be recognized is expected to continue from the first quarter of 2015 through 2019, when we anticipate completing the various research and development services that are specified in the Pfizer Transaction and our performance obligations are completed. We will continue to review the timing of when our research and development services will be completed in order to assess that the estimated performance period over which the revenue is to be recognized is appropriate. Any significant changes in the timing of the performance period will result in a change in the revenue recognition period. We are recognizing the non-refundable $295.0 million upfront payments on a straight-line basis over the performance period. We recognized $30.2 million of revenue related to the Pfizer Transaction in Revenue from transfer of intellectual property in our Condensed Consolidated Statement of Operations during the six months ended June 30, 2015 , and had deferred revenue related to the Pfizer Transaction of $264.8 million at June 30, 2015 . As of June 30, 2015 , $70.6 million of deferred revenue related to the Pfizer Transaction was classified in Accrued expenses and $194.2 million was classified in Other long-term liabilities in our Condensed Consolidated Balance Sheet. The Pfizer Transaction includes milestone payments of $275.0 million upon the achievement of certain milestones. The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets. We evaluated each of these milestone payments and believe that all of the milestones are substantive as (i) there is substantive uncertainty at the close of the Pfizer Transaction that the milestones would be achieved as approval from a regulatory authority must be received to achieve the milestones which would be commensurate with the enhancement of value of the underlying intellectual property, (ii) the milestones relate solely to past performance and (iii) the amount of the milestone is reasonable in relation to the effort expended and the risk associated with the achievement of the milestone. The milestone payments will be recognized as revenue in full in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, no revenue has been recognized related to the achievement of the milestones. In the first quarter of 2015, we made a payment of $25.9 million to the Office of the Chief Scientist of the Israeli Ministry of Economy (“OCS”) in connection with repayment obligations resulting from grants previously made by the OCS to OPKO Biologics to support development of hGH-CTP and the outlicense of the technology outside of Israel. We recognized the $25.9 million payment in Grant repayment expense in our Condensed Consolidated Statement of Operations during the six months ended June 30, 2015 . TESARO In November 2009, we entered into an asset purchase agreement (the “NK-1 Agreement”) under which we acquired rolapitant and other neurokinin-1 (“NK-1”) assets from Merck. In December 2010, we entered into an exclusive license agreement with TESARO, in which we out-licensed the development, manufacture, commercialization and distribution of our lead NK-1 candidate, rolapitant (the “TESARO License”). Under the terms of the license, we received a $6.0 million upfront payment from TESARO and are eligible to receive milestone payments of up to $30 million upon achievement of certain regulatory and commercial sale milestones (of which $5 million has been paid to date) and additional commercial milestone payments of up to $85 million if specified levels of annual net sales are achieved. During the six months ended June 30, 2015 and 2014, no revenue has been recognized related to the achievement of the milestones under the TESARO License. TESARO is also obligated to pay us tiered royalties on annual net sales achieved in the United States and Europe at percentage rates that range from the low double digits to the low twenties, and outside of the United States and Europe at low double-digit percentage rates. TESARO assumed responsibility for clinical development and commercialization of licensed products at its expense. Under the Agreement, we will continue to receive royalties on a country-by-country and product-by-product basis until the later of the date that all of the patent rights licensed from us and covering rolapitant expire, are invalidated or are not enforceable and 12 years from the first commercial sale of the product. If TESARO elects to develop and commercialize rolapitant in Japan through a third-party licensee, TESARO will share equally with us all amounts it receives in connection with such activities, subject to certain exceptions and deductions. In addition, we will have an option to market the products in Latin America. The term of the license will remain in force until the expiration of the royalty term in each country, unless we terminate the license earlier for TESARO’s material breach of the license or bankruptcy. TESARO has a right to terminate the license at any time during the term for any reason on three months’ written notice Under the terms of the NK-1 Agreement, we are required to pay Merck up to an additional $25.0 million upon achievement of certain development milestones. Future payments to be made under the NK-1 Agreement will be recognized when the milestones are achieved and consideration is paid or becomes payable. RXi Pharmaceuticals Corporation In March 2013, we completed the sale to RXi of substantially all of our assets in the field of RNA interference (the “RNAi Assets”) (collectively, the “Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, RXi will be required to pay us up to $50.0 million in milestone payments upon the successful development and commercialization of each drug developed by RXi, certain of its affiliates or any of its or their licensees or sublicensees utilizing patents included within the RNAi Assets (each, a “Qualified Drug”). In addition, RXi will also be required to pay us royalties equal to: (a) a mid single-digit percentage of “Net Sales” (as defined in the Asset Purchase Agreement) with respect to each Qualified Drug sold for an ophthalmologic use during the applicable “Royalty Period” (as defined in the Asset Purchase Agreement); and (b) a low single-digit percentage of net sales with respect to each Qualified Drug sold for a non-ophthalmologic use during the applicable Royalty Period. Other We have completed strategic deals with the UT Southwestern, Washington University, INEOS Healthcare, TSRI, the President and Fellows of Harvard College, and Academia Sinica, among others. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.

Segments

Segments	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
SEGMENTS	SEGMENTS We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel, Spain, Brazil, and Uruguay. The diagnostics segment consists of two operating segments, our (i) pathology operations and (ii) point-of-care and molecular diagnostics operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: For the three months ended June 30, For the six months ended June 30, (In thousands) 2015 2014 2015 2014 Product revenues: Pharmaceuticals $ 22,848 $ 21,392 $ 38,334 $ 41,219 Diagnostics — — — — Corporate — — — — $ 22,848 $ 21,392 $ 38,334 $ 41,219 Revenue from services: Pharmaceuticals $ — $ — $ — $ — Diagnostics 1,848 2,093 3,857 4,003 Corporate 60 60 120 120 $ 1,908 $ 2,153 $ 3,977 $ 4,123 Revenue from transfer of intellectual property: Pharmaceuticals $ 17,673 $ — $ 30,202 $ 285 Diagnostics — — — 191 Corporate — — — — $ 17,673 $ — $ 30,202 $ 476 Operating (loss) income: Pharmaceuticals $ (4,660 ) $ (20,368 ) $ (42,584 ) $ (36,941 ) Diagnostics (7,098 ) (6,805 ) (15,575 ) (13,882 ) Corporate (12,905 ) (7,038 ) (22,882 ) (13,174 ) Less: Operating loss attributable to noncontrolling interests (746 ) (674 ) (1,281 ) (1,163 ) $ (25,409 ) $ (34,885 ) $ (82,322 ) $ (65,160 ) Depreciation and amortization: Pharmaceuticals $ 2,371 $ 2,287 $ 4,138 $ 4,135 Diagnostics 1,754 1,716 3,501 3,408 Corporate 27 24 46 48 $ 4,152 $ 4,027 $ 7,685 $ 7,591 Net loss from investment in investees: Pharmaceuticals $ (804 ) $ (370 ) $ (2,565 ) $ (2,426 ) Diagnostics — — — — Corporate — — — — $ (804 ) $ (370 ) $ (2,565 ) $ (2,426 ) Revenues: United States $ 2,525 $ 2,153 $ 5,019 $ 4,599 Ireland 19,376 — 31,480 — Chile 8,698 7,852 15,150 15,136 Spain 4,920 5,666 8,857 11,815 Israel 5,942 6,307 10,155 10,853 Mexico 968 1,546 1,852 3,377 Other — 21 — 38 $ 42,429 $ 23,545 $ 72,513 $ 45,818 (In thousands) June 30, December 31, Assets: Pharmaceuticals $ 1,290,366 $ 1,064,498 Diagnostics 104,487 108,072 Corporate 130,638 95,094 $ 1,525,491 $ 1,267,664 Goodwill: Pharmaceuticals $ 238,642 $ 173,327 Diagnostics 50,965 50,965 Corporate — — $ 289,607 $ 224,292 During the three and six months ended June 30, 2015 , revenue recognized under the Pfizer Transaction represented 42% of our total revenue. Refer to Note 12. During the three and six months ended June 30, 2014 , one customer represented 21% and 15% of our total revenue, respectively. As of June 30, 2015 and December 31, 2014 , no customer represented more than 10% of our accounts receivable balance.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On July 1, 2015, we announced that our 2033 Senior Notes continue to be convertible by holders of such notes. We have elected to satisfy our conversion obligation under the 2033 Senior Notes in shares of our Common Stock. This conversion right has been triggered because the closing price per share of our Common Stock has exceeded $9.19 , or 130% of the initial conversion price of $7.07 , for at least 20 of 30 consecutive trading days during the period ending on June 30, 2015 . The conversion right was previously triggered during the quarter ended March 31, 2015. The 2033 Senior Notes will continue to be convertible until September 30, 2015, and may be convertible thereafter, if one or more of the conversion conditions specified in the Indenture, dated as of January 30, 2013, by and between the Company and Wells Fargo Bank N.A., is satisfied during future measurement periods. Pursuant to the Indenture, a holder who elects to convert the 2033 Senior Notes will receive 141.4827 shares of our Common Stock plus such number of additional shares as is applicable on the conversion date per $1,000 principal amount of 2033 Senior Notes based on the early conversion provisions in the Indenture. In May 2015, we submitted a New Drug Application (NDA) for oral Rayaldee to the U.S. Food and Drug Administration (FDA). The NDA requests marketing approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. Under the terms of the agreement for our acquisition of OPKO Renal, we will pay the former owners of OPKO Renal $20.0 million upon the acceptance of the NDA by the FDA, which is payable in either shares of our Common Stock or cash, at our option. Our NDA was accepted by the FDA in July 2015. We have reviewed all subsequent events and transactions that occurred after the date of our June 30, 2015 Condensed Consolidated Balance Sheet date, through the time of filing this Quarterly Report on Form 10-Q.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three and six months ended June 30, 2015 , are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2015 or any future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014 .
Principles of consolidation	Principles of consolidation . The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and of our wholly-owned subsidiaries and a variable interest entity in which we are deemed to be the primary beneficiary. All intercompany accounts and transactions are eliminated in consolidation.
Use of estimates	Use of estimates . The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.
Cash and cash equivalents	Cash and cash equivalents. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.
Inventories	Inventories . Inventories are valued at the lower of cost or market (net realizable value). Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost or market. Pre-launch inventories . We may accumulate commercial quantities of certain product candidates prior to the date we anticipate that such products will receive final U.S. FDA approval. The accumulation of such pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever. This risk notwithstanding, we may accumulate pre-launch inventories of certain products when such action is appropriate in relation to the commercial value of the product launch opportunity. In accordance with our policy, this pre-launch inventory is expensed.
Goodwill and intangible assets	Goodwill and intangible assets . Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired when accounted for by the purchase method of accounting and arose from our acquisitions of Pharma Genexx, S.A. (“OPKO Chile”), Pharmacos Exakta S.A. de C.V. (“OPKO Mexico”), CURNA, Inc. (“CURNA”), Claros Diagnostics, Inc. (“OPKO Diagnostics”), FineTech Pharmaceuticals, Ltd. (“FineTech”), ALS Distribuidora Limitada (“ALS”), Farmadiet Group Holding, S.L. (“OPKO Health Europe”), previously known as OPKO Spain, Prost-Data, Inc. (“OPKO Lab”), Cytochroma Inc. (“OPKO Renal”), Silcon Comércio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos Ltda. (“OPKO Brazil”), PROLOR Biotech, Inc. (“OPKO Biologics”) and EirGen Pharma Limited ("EirGen"). Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions at June 30, 2015 and December 31, 2014 were $1.2 billion and $1.1 billion , respectively. Assets acquired and liabilities assumed in business combinations, licensing and other transactions are recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. We determined the fair value of intangible assets, including IPR&D, using the “income method.” Goodwill is tested at least annually for impairment, or when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that its fair value exceeds the carrying value. Intangible assets are tested for impairment whenever events or changes in circumstances warrant a review, although IPR&D is required to be tested at least annually until the project is completed or abandoned. Upon obtaining regulatory approval, the IPR&D asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the IPR&D asset is charged to expense. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, currently ranging from 3 to 20 years, and review for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up.
Fair value measurements	Fair value measurements . The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term maturities of these instruments. Investments that are considered available for sale as of June 30, 2015 and December 31, 2014, are carried at fair value. Short-term investments, which we invest in from time to time, include bank deposits, corporate notes, U.S. treasury securities and U.S. government agency securities with original maturities of greater than 90 days and remaining maturities of less than one year . Long-term investments include corporate notes, U.S. treasury securities and U.S. government agency securities with maturities greater than one year . In evaluating fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.
Contingent consideration	Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as contingent consideration income. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.
Derivative financial instruments	Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations, when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet specific hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At June 30, 2015 and December 31, 2014 , our forward contracts for inventory purchases did not meet the hedge effectiveness requirements to be designated as hedges. Accordingly, we recognize all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations.
Revenue recognition	Revenue recognition. Generally, we recognize revenue from product sales when goods are shipped and title and risk of loss transfer to our customers. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and management’s evaluation of specific factors that may increase or decrease the risk of product returns. Revenue for laboratory services is recognized on the accrual basis at the time test results are reported, which approximates when services are provided. Services are provided to certain patients covered by various third-party payer programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services under third-party payer programs are included in revenue net of allowances for contractual discounts and allowances for differences between the amounts billed and estimated program payment amounts. Adjustments to the estimated payment amounts based on final settlement with the programs are recorded upon settlement as an adjustment to revenue. Revenue from transfer of intellectual property includes revenue related to the sale, license or transfer of intellectual property such as upfront license payments, license fees and milestone payments received through our license, collaboration and commercialization agreements. We analyze our multiple-element arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. Non-refundable license fees for the out-license of our technology are recognized depending on the provisions of each agreement. We recognize non-refundable upfront license payments as revenue upon receipt if the license has standalone value and qualifies for treatment as a separate unit of accounting under multiple-element arrangement guidance. License fees with ongoing involvement or performance obligations that do not have standalone value are recorded as deferred revenue, included in Accrued expenses or Other long-term liabilities, when received and generally are recognized ratably over the period of such performance obligations only after both the license period has commenced and we have delivered the technology. The assessment of our obligations and related performance periods requires significant management judgment. If an agreement contains research and development obligations, the relevant time period for the research and development phase is based on management estimates and could vary depending on the outcome of clinical trials and the regulatory approval process. Such changes could materially impact the revenue recognized, and as a result, management reviews the estimates related to the relevant time period of research and development on a quarterly basis. For the three and six months ended June 30, 2015 , revenue from transfer of intellectual property includes $17.7 million and $30.2 million , respectively, of revenue related to the Pfizer Transaction. Refer to Note 12. Revenue from milestone payments related to arrangements under which we have continuing performance obligations are recognized as Revenue from transfer of intellectual property upon achievement of the milestone only if all of the following conditions are met: the milestone payments are non-refundable; there was substantive uncertainty at the date of entering into the arrangement that the milestone would be achieved; the milestone is commensurate with either the vendor’s performance to achieve the milestone or the enhancement of the value of the delivered item by the vendor; the milestone relates solely to past performance; and the amount of the milestone is reasonable in relation to the effort expended or the risk associated with the achievement of the milestone. If any of these conditions are not met, the milestone payments are not considered to be substantive and are, therefore, deferred and recognized as Revenue from transfer of intellectual property over the term of the arrangement as we complete our performance obligations.
Allowance for doubtful accounts	Allowance for doubtful accounts . We assess the collectability of accounts receivable balances by considering factors such as historical experience, customer credit worthiness, the age of accounts receivable balances and current economic conditions and trends that may affect a customer's ability to pay. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts. Our reported net loss is directly affected by our estimate of the collectability of accounts receivable.
Equity-based compensation	Equity-based compensation. We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits, realized from the exercise of stock options as a financing cash inflow and as a reduction of taxes paid in cash flow from operations. Equity-based compensation arrangements to non-employees are recorded at their fair value on the measurement date. The measurement of equity-based compensation to non-employees is subject to periodic adjustment as the underlying equity instruments vest.
Research and development expenses	Research and development expenses. Research and development expenses include external and internal expenses, partially offset by third-party grants and fundings arising from collaboration agreements. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and stock-based compensation expense. Other unallocated internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract. We record expense for in-process research and development projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining useful life.
Segment reporting	Segment reporting . Our chief operating decision-maker (“CODM”) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Our CODM reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceutical segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Variable interest entities	Variable interest entities . The consolidation of variable interest entities (“VIE”) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE.
Investments	Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or investments available for sale based on our percentage of ownership and whether we have significant influence over the operations of the investees. Investments for which it is not practical to estimate fair value and which we do not have significant influence are accounted for as cost method investments. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 5. For investments classified as available for sale, we record changes in their fair value as unrealized gain or loss in Other comprehensive income (loss) based on their closing price per share at the end of each reporting period.
Income Taxes	Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment.
Recent accounting pronouncements	Recent accounting pronouncements. In May 2014, the FASB issued Accounting Standards Update (“ASU”), ASU No. 2014-09, "Revenue from Contracts with Customers." ASU No. 2014-09 clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. ASU No. 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Companies can choose to apply the ASU using either the full retrospective approach or a modified retrospective approach. We are currently evaluating both methods of adoption and the impact that the adoption of this ASU will have on our Condensed Consolidated Financial Statements. In June 2014, the FASB issued ASU No. 2014-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (a consensus of the FASB Emerging Issues Task Force)." ASU No. 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU No. 2014-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Earlier adoption is permitted. The amendments can be applied either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards. We expect to apply the ASU prospectively and do not expect the adoption to have an impact on our Condensed Consolidated Financial Statements. In August 2014, the FASB issued ASU No. 2014-15, "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern," to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 with early adoption permitted. We do not believe the impact of our pending adoption of ASU 2014-15 on our Condensed Consolidated Financial Statements will be material. In February 2015, the FASB issued ASU No. 2015-02, "Consolidation (Topic 810)," which amends current consolidation guidance including changes to both the variable and voting interest models used by companies to evaluate whether an entity should be consolidated. The requirements from ASU 2015-02 are effective for interim and annual periods beginning after December 15, 2015, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

Composition of Certain Financ23

Composition of Certain Financial Statement Captions (Tables)	6 Months Ended
	Jun. 30, 2015
Compositions of Certain Financial Statement Captions [Abstract]
Composition of certain financial statement captions	(In thousands) June 30, December 31, Accounts receivable, net Accounts receivable $ 29,045 $ 21,875 Less: allowance for doubtful accounts (2,065 ) (1,906 ) $ 26,980 $ 19,969 Inventories, net Finished products $ 13,830 $ 12,116 Work in-process 1,619 1,011 Raw materials 5,782 4,116 Less: inventory reserve (712 ) (639 ) $ 20,519 $ 16,604 Prepaid expenses and other current assets Prepaid supplies $ 1,441 $ 1,123 Prepaid insurance 613 968 Other receivables 1,107 669 Taxes recoverable 3,074 2,417 Other 3,388 4,212 $ 9,623 $ 9,389 Intangible assets, net: Technologies $ 52,287 $ 52,508 Customer relationships 55,750 22,108 Product registrations 8,088 8,763 Trade names 3,411 3,483 Covenants not to compete 8,620 8,639 Other 4,889 1,079 Less: accumulated amortization (38,798 ) (33,931 ) $ 94,247 $ 62,649 Accrued expenses: Taxes payable $ 2,592 $ 77 Deferred revenue 75,159 4,185 Clinical trials 8,534 8,643 Professional fees 1,724 1,860 Employee benefits 5,456 4,127 Contingent consideration 41,146 27,352 Other 15,232 14,668 $ 149,843 $ 60,912 (In thousands) June 30, December 31, Other long-term liabilities: Contingent consideration – OPKO Renal $ 19,183 $ 36,529 Contingent consideration – OPKO Health Europe 225 254 Contingent consideration – OPKO Diagnostics 13,342 6,992 Contingent consideration – CURNA 433 440 Mortgages and other debts payable 2,148 2,434 Deferred tax liabilities 172,458 167,153 Deferred revenue 197,279 2,526 Other 3,753 1,030 $ 408,821 $ 217,358
Schedule of goodwill	The following table reflects the changes in Goodwill during the six months ended June 30, 2015 . 2015 (In thousands) Balance at January 1st Acquisitions Foreign exchange Balance at June 30th Pharmaceuticals CURNA $ 4,827 $ — $ — $ 4,827 OPKO Mexico 100 — (5 ) 95 OPKO Chile 5,283 — (243 ) 5,040 OPKO Health Europe 8,013 — (699 ) 7,314 FineTech 11,698 — — 11,698 SciVac 1,553 — 49 1,602 OPKO Renal 2,069 — — 2,069 OPKO Biologics 139,784 — — 139,784 EirGen Pharma Ltd — 66,823 (610 ) 66,213 Diagnostics OPKO Diagnostics 17,977 — — 17,977 OPKO Lab 32,988 — — 32,988 $ 224,292 $ 66,823 $ (1,508 ) $ 289,607

Acquisitions, Investments, an24

Acquisitions, Investments, and Licenses (Tables)	6 Months Ended
	Jun. 30, 2015
Business Acquisition [Line Items]
Maximum exposure of unconsolidated investments	The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2015 : (in thousands) Investment type Investment Carrying Value Underlying Equity in Net Assets Equity method investments $ 6,746 $ 23,735 Variable interest entity, equity method 903 — Available for sale investments 3,816 Warrants and options 9,969 Total carrying value of investments $ 21,434
EirGen Pharma Ltd
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of EirGen at the date of acquisition. The purchase price allocation for EirGen is preliminary: (In thousands) EirGen Current assets (1) $ 11,795 Intangible assets: IPR&D assets 19,597 Customer relationships 34,155 Currently marketed products 3,919 Total intangible assets 57,671 Goodwill 66,823 Property, plant and equipment 8,117 Other assets 1,232 Accounts payable and other liabilities (6,254 ) Deferred tax liability (5,618 ) Total purchase price $ 133,766 (1) Current assets include cash, accounts receivable, inventory and other assets of $5.5 million , $2.7 million , $2.2 million and $1.4 million , respectively, related to the EirGen acquisition. The fair value of the accounts receivable equals the gross contractual amount at the date of acquisition.
Schedule of Pro Forma	The following table includes the pro forma results for the three and six months ended June 30, 2015 and 2014 of the combined companies as though the acquisition of EirGen had been completed as of the beginning of the period presented. For the three months ended June 30, For the six months ended June 30, (In thousands) 2015 2014 2015 2014 Revenues $43,848 $25,659 $76,769 $50,185 Net loss (43,420) (28,356) (162,331) (75,879) Net loss attributable to common shareholders (42,945) (27,759) (160,931) (74,742) Basic and diluted net loss per share $(0.09) $(0.07) $(0.35) $(0.18)
SciVac
Business Acquisition [Line Items]
Summary of consolidated assets and non-recourse liabilities related to SciVac	The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of June 30, 2015 and December 31, 2014. These assets are owned by, and these liabilities are obligations of, SciVac, not us. (In thousands) June 30, December 31, 2014 Assets Current assets: Cash and cash equivalents $ 21 $ 393 Accounts receivable, net 304 316 Inventories, net 1,433 1,649 Prepaid expenses and other current assets 774 718 Total current assets 2,532 3,076 Property, plant and equipment, net 1,791 1,725 Intangible assets, net 843 875 Goodwill 1,602 1,553 Other assets 368 384 Total assets $ 7,136 $ 7,613 Liabilities Current liabilities: Accounts payable $ 900 $ 445 Accrued expenses 4,476 4,446 Notes payable 5,409 5,189 Total current liabilities 10,785 10,080 Other long-term liabilities 1,884 2,042 Total liabilities $ 12,669 $ 12,122

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Instrument [Line Items]
Schedule of principal amounts, unamortized discount and net carrying amounts	The following table sets forth information related to the 2033 Senior Notes which is included our Condensed Consolidated Balance Sheets as of June 30, 2015 : (In thousands) Embedded conversion option 2033 Senior Notes Discount Total Balance at December 31, 2014 $ 65,947 $ 87,642 $ (22,135 ) $ 131,454 Amortization of debt discount — — 1,680 1,680 Change in fair value of embedded derivative 67,950 — — 67,950 Conversion (60,346 ) (41,442 ) 9,907 (91,881 ) Balance at June 30, 2015 $ 73,551 $ 46,200 $ (10,548 ) $ 109,203
Summary of lines of credit	The following table summarizes the amounts outstanding under the Chilean and Spanish lines of credit: (Dollars in thousands) Balance Outstanding Lender Interest rate on borrowings at June 30, 2015 Credit line capacity June 30, December 31, 2014 Itau Bank 6.00% $1,800 $1,171 $965 Bank of Chile 5.50% 2,250 1,572 1,410 BICE Bank 6.16% 2,300 1,088 1,249 BBVA Bank 5.00% 2,300 1,552 795 Penta Bank 7.58% 1,200 631 1,008 Security Bank 6.16% 940 305 361 Estado Bank 5.30% 2,800 2,039 1,870 BBVA Bank 4.75% 277 — — Total $13,867 $8,358 $7,658
OPKO Health Europe
Debt Instrument [Line Items]
Schedule of principal amounts, unamortized discount and net carrying amounts	At June 30, 2015 and December 31, 2014 , we had mortgage notes and other debt related to OPKO Health Europe and EirGen as follows: (In thousands) June 30, December 31, 2014 Current portion of notes payable $ 832 $ 608 Other long-term liabilities 2,393 2,435 Total mortgage notes and other debt $ 3,225 $ 3,043
Notes
Debt Instrument [Line Items]
Inputs to lattice model used to value the embedded derivative	The following table sets forth the inputs to the lattice model used to value the embedded derivative: June 30, 2015 Stock price $16.08 Conversion Rate 141.4827 Conversion Price $7.07 Maturity date February 1, 2033 Risk-free interest rate 1.19% Estimated stock volatility 41% Estimated credit spread 1,133 basis points
Fair value of notes with and without the embedded derivatives and fair value of embedded derivatives	The following table sets forth the fair value of the 2033 Senior Notes with and without the embedded derivatives, and the fair value of the embedded derivatives at June 30, 2015 . At June 30, 2015 the principal amount of the 2033 Senior Notes was $46.2 million : (In thousands) June 30, 2015 Fair value of 2033 Senior Notes: With the embedded derivatives $ 107,743 Without the embedded derivatives $ 34,192 Estimated fair value of the embedded derivatives $ 73,551

Accumulated Other Comprehensi26

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Changes in accumulated other comprehensive income net of tax	For the six months ended June 30, 2015 , changes in Accumulated other comprehensive income (loss), net of tax, were as follows: (In thousands) Foreign currency Unrealized gain (loss) in Accumulated OCI Total Balance at December 31, 2014 $ (6,717 ) $ (5,675 ) $ (12,392 ) Other comprehensive income before reclassifications, net of tax (4,547 ) (1,941 ) (6,488 ) Amounts reclassified from accumulated other comprehensive income, net of tax — — — Net other comprehensive loss (4,547 ) (1,941 ) (6,488 ) Balance at June 30, 2015 $ (11,264 ) $ (7,616 ) $ (18,880 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Summary of investments classified as available for sale, and carried at fair value	A summary of our investments classified as available for sale and carried at fair value, is as follows: As of June 30, 2015 (In thousands) Amortized Cost Gross unrealized gains in Accumulated OCI Gross unrealized losses in Accumulated OCI Gain/(Loss) in Accumulated Deficit Fair value Common stock investments, available for sale $ 11,479 $ 898 $ (7,119 ) $ (1,442 ) $ 3,816 Common stock options/warrants 3,925 — — 6,044 9,969 Total assets $ 15,404 $ 898 $ (7,119 ) $ 4,602 $ 13,785 As of December 31, 2014 (In thousands) Amortized Cost Gross unrealized gains in Accumulated OCI Gross unrealized losses in Accumulated OCI Gain/(Loss) in Accumulated Deficit Fair value Common stock investments, available for sale $ 11,479 $ 293 $ (4,573 ) $ (1,441 ) $ 5,758 Common stock options/warrants 1,425 216 — 4,673 6,314 Total assets $ 12,904 $ 509 $ (4,573 ) $ 3,232 $ 12,072
Financial assets and liabilities measured at fair value on a recurring basis	Our financial assets and liabilities measured at fair value on a recurring basis are as follows: Fair value measurements as of June 30, 2015 (In thousands) Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Money market funds $ 52,563 $ — $ — $ 52,563 Common stock investments, available for sale 3,816 — — 3,816 Common stock options/warrants — 9,969 — 9,969 Forward contracts — 115 — 115 Total assets $ 56,379 $ 10,084 $ — $ 66,463 Liabilities: Embedded conversion option $ — $ — $ 73,551 $ 73,551 Contingent consideration: CURNA — — 433 433 OPKO Diagnostics — — 13,342 13,342 OPKO Renal — — 60,090 60,090 OPKO Health Europe — — 464 464 Total liabilities $ — $ — $ 147,880 $ 147,880 Fair value measurements as of December 31, 2014 (In thousands) Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Money market funds $ 71,286 $ — $ — $ 71,286 Common stock investments, available for sale 5,758 — — 5,758 Common stock options/warrants — 6,314 — 6,314 Forward contracts — 36 — 36 Total assets $ 77,044 $ 6,350 $ — $ 83,394 Liabilities: Embedded conversion option $ — $ — $ 65,947 $ 65,947 Contingent consideration: CURNA — — 440 440 OPKO Diagnostics — — 13,578 13,578 OPKO Renal — — 55,780 55,780 OPKO Health Europe — — 1,769 1,769 Total liabilities $ — $ — $ 137,514 $ 137,514
The carrying amount and estimated fair value of our long-term debt	The fair value of the 2033 Senior Notes is determined using a binomial lattice approach in order to estimate the fair value of the embedded derivative in the 2033 Senior Notes. Refer to Note 6. June 30, 2015 (In thousands) Carrying Value Total Fair Value Level 1 Level 2 Level 3 2033 Senior Notes $ 35,652 $ 34,192 $ — $ — $ 34,192
Reconcile the beginning and ending balances of Level 3 assets and liabilities	The following tables reconcile the beginning and ending balances of our Level 3 assets and liabilities as of June 30, 2015 : June 30, 2015 (In thousands) Contingent consideration Embedded conversion option Balance at December 31, 2014 $ 71,567 $ 65,947 Total losses (gains) for the period: Included in results of operations 4,836 67,950 Foreign currency impact (261 ) — Payments (1,813 ) — Conversion — (60,346 ) Balance at June 30, 2015 $ 74,329 $ 73,551

Derivative Contracts (Tables)

Derivative Contracts (Tables)	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of fair values and derivative financial instrument	The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets: (In thousands) Balance Sheet Component June 30, December 31, Derivative financial instruments: Common Stock options/warrants Investments, net $ 9,969 $ 6,314 Embedded conversion option 2033 Senior Notes, net of discount and estimated fair value of embedded derivatives $ 73,551 $ 65,947 Forward contracts Unrealized gains on forward contracts are recorded in Prepaid expenses and other current assets. Unrealized losses on forward contracts are recorded in Accrued expenses. $ 115 $ 36
Summary of (losses) and gains recorded in Fair value changes of derivative financial instruments	The following table summarizes the losses and gains recorded for the three and six months ended June 30, 2015 and 2014: Three months ended June 30, Six months ended June 30, (In thousands) 2015 2014 2015 2014 Derivative gain (loss): Common Stock options/warrants (1) $ (2,446 ) $ (860 ) $ 1,425 $ (263 ) 2033 Senior Notes (14,220 ) 11,882 (67,950 ) 770 Forward contracts 110 (55 ) 181 87 Total $ (16,556 ) $ 10,967 $ (66,344 ) $ 594 (1) Amount for 2014 includes the Pharmsynthez Note Receivable and the Purchase Option.
Outstanding contracts recorded at fair value and their maturity details	The outstanding forward contracts at June 30, 2015 and December 31, 2014 , have been recorded at fair value, and their maturity details are as follows: (In thousands) Days until maturity Contract value Fair value at June 30, 2015 Effect on income (loss) 0 to 30 $ 1,414 $ 1,466 $ 52 31 to 60 324 336 12 61 to 90 939 981 42 91 to 120 180 188 8 More than 120 31 32 1 Total $ 2,888 $ 3,003 $ 115 (In thousands) Days until maturity Contract value Fair value at December 31, 2014 Effect on income (loss) 0 to 30 $ 750 $ 780 $ 30 31 to 60 90 93 3 61 to 90 — — — 91 to 120 68 71 3 121 to 180 — — — More than 180 — — — Total $ 908 $ 944 $ 36

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Information regarding our geographic activities	Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: For the three months ended June 30, For the six months ended June 30, (In thousands) 2015 2014 2015 2014 Product revenues: Pharmaceuticals $ 22,848 $ 21,392 $ 38,334 $ 41,219 Diagnostics — — — — Corporate — — — — $ 22,848 $ 21,392 $ 38,334 $ 41,219 Revenue from services: Pharmaceuticals $ — $ — $ — $ — Diagnostics 1,848 2,093 3,857 4,003 Corporate 60 60 120 120 $ 1,908 $ 2,153 $ 3,977 $ 4,123 Revenue from transfer of intellectual property: Pharmaceuticals $ 17,673 $ — $ 30,202 $ 285 Diagnostics — — — 191 Corporate — — — — $ 17,673 $ — $ 30,202 $ 476 Operating (loss) income: Pharmaceuticals $ (4,660 ) $ (20,368 ) $ (42,584 ) $ (36,941 ) Diagnostics (7,098 ) (6,805 ) (15,575 ) (13,882 ) Corporate (12,905 ) (7,038 ) (22,882 ) (13,174 ) Less: Operating loss attributable to noncontrolling interests (746 ) (674 ) (1,281 ) (1,163 ) $ (25,409 ) $ (34,885 ) $ (82,322 ) $ (65,160 ) Depreciation and amortization: Pharmaceuticals $ 2,371 $ 2,287 $ 4,138 $ 4,135 Diagnostics 1,754 1,716 3,501 3,408 Corporate 27 24 46 48 $ 4,152 $ 4,027 $ 7,685 $ 7,591 Net loss from investment in investees: Pharmaceuticals $ (804 ) $ (370 ) $ (2,565 ) $ (2,426 ) Diagnostics — — — — Corporate — — — — $ (804 ) $ (370 ) $ (2,565 ) $ (2,426 ) Revenues: United States $ 2,525 $ 2,153 $ 5,019 $ 4,599 Ireland 19,376 — 31,480 — Chile 8,698 7,852 15,150 15,136 Spain 4,920 5,666 8,857 11,815 Israel 5,942 6,307 10,155 10,853 Mexico 968 1,546 1,852 3,377 Other — 21 — 38 $ 42,429 $ 23,545 $ 72,513 $ 45,818 (In thousands) June 30, December 31, Assets: Pharmaceuticals $ 1,290,366 $ 1,064,498 Diagnostics 104,487 108,072 Corporate 130,638 95,094 $ 1,525,491 $ 1,267,664 Goodwill: Pharmaceuticals $ 238,642 $ 173,327 Diagnostics 50,965 50,965 Corporate — — $ 289,607 $ 224,292

Business and Organization (Deta

Business and Organization (Details) $ / shares in Units, $ in Millions	Jun. 03, 2015USD ($)$ / shares	May. 05, 2015USD ($)$ / sharesshares
Bio-Reference
Business Acquisition [Line Items]
Consideration transferred	$ 1,300
EirGen Pharma Ltd
Business Acquisition [Line Items]
Consideration transferred		$ 133.8
Cash paid at closing date		100.2
Common stock value		$ 33.6
Common Stock
Business Acquisition [Line Items]
Stock price | $ / shares		$ 13.88
Common Stock | Bio-Reference
Business Acquisition [Line Items]
Conversion ratio on stock	2.75
Stock price | $ / shares	$ 16.74
Acquired entity share price | $ / shares	$ 46.04
Common Stock | EirGen Pharma Ltd
Business Acquisition [Line Items]
Delivery of common stock | shares		2,420,487

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Segment	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Summary of Significant Accounting Policies [Line Items]
Goodwill and intangible assets	$ 1,200,000		$ 1,200,000		$ 1,100,000
Amortization of intangible assets	3,236	$ 2,826	5,901	$ 5,569
Revenue from transfer of intellectual property	17,673	$ 0	30,202	476
Total deferred revenue related to other revenues	272,400		272,400		6,700
Allowance for doubtful accounts receivable	$ 2,065		2,065		$ 1,906
Equity-based compensation expense for continuing operations			$ 14,090	$ 6,993
Number of reportable segments | Segment			2
Accrual for uncertain tax positions			$ 2,300
Pharmaceuticals
Summary of Significant Accounting Policies [Line Items]
Number of operating segments | Segment			2
Diagnostics
Summary of Significant Accounting Policies [Line Items]
Number of operating segments | Segment			2
Minimum
Summary of Significant Accounting Policies [Line Items]
Intangible assets, estimated useful lives			3 years
Estimate of possible loss			$ 0
Maximum
Summary of Significant Accounting Policies [Line Items]
Intangible assets, estimated useful lives			20 years
Estimate of possible loss			$ 50,000

Loss Per Share (Details)

Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of common stock warrant and common stock options exercised	2,106,679		24,168,461
Number of common stock issued for stock warrant and stock options exercised	2,106,634		22,635,661
Shares surrendered in lieu of cash payment	45		1,206,654
Common stock investments, available for sale
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common shares	11,261,582	29,132,527	14,375,502	29,503,319

Composition of Certain Financ33

Composition of Certain Financial Statement Captions (Details) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Accounts receivable, net
Accounts receivable		$ 29,045	$ 21,875
Less: allowance for doubtful accounts		(2,065)	(1,906)
Accounts receivable, net	[1]	26,980	19,969
Inventories, net
Finished products		13,830	12,116
Work in-process		1,619	1,011
Raw materials		5,782	4,116
Less: inventory reserve		(712)	(639)
Inventory, net	[1]	20,519	16,604
Prepaid expenses and other current assets
Prepaid supplies		1,441	1,123
Prepaid insurance		613	968
Other receivables		1,107	669
Taxes recoverable		3,074	2,417
Other		3,388	4,212
Prepaid expenses and other current assets	[1]	9,623	9,389
Intangible assets, net:
Less: accumulated amortization		(38,798)	(33,931)
Intangible assets, net	[1]	94,247	62,649
Accrued expenses:
Taxes payable		2,592	77
Deferred revenue		75,159	4,185
Clinical trials		8,534	8,643
Professional fees		1,724	1,860
Employee benefits		5,456	4,127
Contingent consideration		41,146	27,352
Other		15,232	14,668
Accrued expenses	[1]	149,843	60,912
Other long-term liabilities:
Mortgages and other debts payable		2,148	2,434
Deferred tax liabilities		172,458	167,153
Deferred revenue		197,279	2,526
Other		3,753	1,030
Other long-term liabilities	[1]	408,821	217,358
OPKO Renal
Other long-term liabilities:
Contingent consideration		19,183	36,529
OPKO Health Europe
Other long-term liabilities:
Contingent consideration		225	254
Mortgages and other debts payable		2,393	2,435
OPKO Diagnostics
Other long-term liabilities:
Contingent consideration		13,342	6,992
CURNA
Other long-term liabilities:
Contingent consideration		433	440
Technologies
Intangible assets, net:
Intangible assets		52,287	52,508
Customer relationships
Intangible assets, net:
Intangible assets		55,750	22,108
Product registrations
Intangible assets, net:
Intangible assets		8,088	8,763
Trade names
Intangible assets, net:
Intangible assets		3,411	3,483
Covenants not to compete
Intangible assets, net:
Intangible assets		8,620	8,639
Other
Intangible assets, net:
Intangible assets		$ 4,889	$ 1,079
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Composition of Certain Financ34

Composition of Certain Financial Statement Captions - Changes in Goodwill (Details) $ in Thousands		6 Months Ended
		Jun. 30, 2015USD ($)
Goodwill [Roll Forward]
Beginning balance	[1]	$ 224,292
Acquisitions		66,823
Foreign exchange		(1,508)
Ending balance	[1]	289,607
Pharmaceuticals | CURNA
Goodwill [Roll Forward]
Beginning balance		4,827
Acquisitions		0
Foreign exchange		0
Ending balance		4,827
Pharmaceuticals | OPKO Mexico
Goodwill [Roll Forward]
Beginning balance		100
Acquisitions		0
Foreign exchange		(5)
Ending balance		95
Pharmaceuticals | OPKO Chile
Goodwill [Roll Forward]
Beginning balance		5,283
Acquisitions		0
Foreign exchange		(243)
Ending balance		5,040
Pharmaceuticals | OPKO Health Europe
Goodwill [Roll Forward]
Beginning balance		8,013
Acquisitions		0
Foreign exchange		(699)
Ending balance		7,314
Pharmaceuticals | FineTech
Goodwill [Roll Forward]
Beginning balance		11,698
Acquisitions		0
Foreign exchange		0
Ending balance		11,698
Pharmaceuticals | SciVac
Goodwill [Roll Forward]
Beginning balance		1,553
Acquisitions		0
Foreign exchange		49
Ending balance		1,602
Pharmaceuticals | OPKO Renal
Goodwill [Roll Forward]
Beginning balance		2,069
Acquisitions		0
Foreign exchange		0
Ending balance		2,069
Pharmaceuticals | OPKO Biologics
Goodwill [Roll Forward]
Beginning balance		139,784
Acquisitions		0
Foreign exchange		0
Ending balance		139,784
Pharmaceuticals | EirGen Pharma Ltd
Goodwill [Roll Forward]
Beginning balance		0
Acquisitions		66,823
Foreign exchange		(610)
Ending balance		66,213
Diagnostics | OPKO Diagnostics
Goodwill [Roll Forward]
Beginning balance		17,977
Acquisitions		0
Foreign exchange		0
Ending balance		17,977
Diagnostics | OPKO Lab
Goodwill [Roll Forward]
Beginning balance		32,988
Acquisitions		0
Foreign exchange		0
Ending balance		$ 32,988
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Acquisitions, Investments, an35

Acquisitions, Investments, and Licenses - Acquisition Narrative (Details) $ / shares in Units, $ in Thousands	Jun. 03, 2015USD ($)$ / shares	May. 05, 2015USD ($)$ / sharesshares	Apr. 17, 2014USD ($)shares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Business Acquisition [Line Items]
In-process research and development				$ 0	$ 10,055	$ 0	$ 10,055
Common Stock
Business Acquisition [Line Items]
Stock price | $ / shares		$ 13.88
Bio-Reference
Business Acquisition [Line Items]
Consideration transferred	$ 1,300,000
Bio-Reference | Common Stock
Business Acquisition [Line Items]
Conversion ratio on stock	2.75
Stock price | $ / shares	$ 16.74
Acquired entity share price | $ / shares	$ 46.04
EirGen Pharma Ltd
Business Acquisition [Line Items]
Consideration transferred		$ 133,800
Cash paid at closing date		100,200
Common stock value		$ 33,600
Revenues						2,300
Net loss						(800)
EirGen Pharma Ltd | Common Stock
Business Acquisition [Line Items]
Delivery of common stock | shares		2,420,487
Inspiro
Business Acquisition [Line Items]
Cash paid at closing date			$ 1,500
Delivery of common stock | shares			999,556
Common stock value			$ 8,600
Inspiro stock purchase agreement percent			100.00%
In-process research and development			$ 10,100
Selling, General and Administrative Expenses | EirGen Pharma Ltd
Business Acquisition [Line Items]
Acquisition related costs						$ 500
Minimum | IPR&D assets | EirGen Pharma Ltd
Business Acquisition [Line Items]
Useful life		3 years
Maximum | IPR&D assets | EirGen Pharma Ltd
Business Acquisition [Line Items]
Useful life		20 years

Acquisitions, Investments, an36

Acquisitions, Investments, and Licenses - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands		Jun. 30, 2015	May. 05, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	[1]	$ 289,607		$ 224,292
EirGen Pharma Ltd
Business Acquisition [Line Items]
Current assets	[2]		$ 11,795
Intangible assets			57,671
Goodwill			66,823
Property, plant and equipment			8,117
Other assets			1,232
Accounts payable and other liabilities			(6,254)
Deferred tax liability			(5,618)
Total purchase price			133,766
Cash			5,500
Accounts receivables			2,700
Inventory			2,200
Other assets			1,400
IPR&D assets | EirGen Pharma Ltd
Business Acquisition [Line Items]
Intangible assets			19,597
Customer relationships | EirGen Pharma Ltd
Business Acquisition [Line Items]
Intangible assets			34,155
Currently marketed products | EirGen Pharma Ltd
Business Acquisition [Line Items]
Intangible assets			$ 3,919
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.
[2]	Current assets include cash, accounts receivable, inventory and other assets of $5.5 million, $2.7 million, $2.2 million and $1.4 million, respectively, related to the EirGen acquisition. The fair value of the accounts receivable equals the gross contractual amount at the date of acquisition.

Acquisitions, Investments, an37

Acquisitions, Investments, and Licenses - Schedule of Pro Forma (Details) - EirGen Pharma Ltd - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Revenues	$ 43,848	$ 25,659	$ 76,769	$ 50,185
Net loss	(43,420)	(28,356)	(162,331)	(75,879)
Net loss attributable to common shareholders	$ (42,945)	$ (27,759)	$ (160,931)	$ (74,742)
Basic and diluted net loss per share (USD per share)	$ (0.09)	$ (0.07)	$ (0.35)	$ (0.18)

Acquisitions, Investments, an38

Acquisitions, Investments, and Licenses - Summary of Investments (Details) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Business Combinations [Abstract]
Equity method investments, investment carrying value		$ 6,746
Equity method investment, underlying equity in net assets		23,735
Variable interest entity, equity method		903
Available for sale investments		3,816
Warrants and options		9,969
Total carrying value of investments	[1]	$ 21,434	$ 22,453
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Acquisitions, Investments, an39

Acquisitions, Investments, and Licenses - Equity Method Investments Narrative (Details) - Jun. 30, 2015 - USD ($) $ in Millions	Total
Schedule of Equity Method Investments [Line Items]
Total assets of equity method investees	$ 403.2
Total liabilities of equity method investees	(96.7)
Net losses of equity method investees	(52.5)
Market value	$ 88.1
Pharmsynthez
Schedule of Equity Method Investments [Line Items]
Ownership percentage	17.00%
Cocrystal
Schedule of Equity Method Investments [Line Items]
Ownership percentage	8.00%
Sevion
Schedule of Equity Method Investments [Line Items]
Ownership percentage	4.00%
Non-Invasive Monitoring Systems, Inc.
Schedule of Equity Method Investments [Line Items]
Ownership percentage	1.00%
Neovasc
Schedule of Equity Method Investments [Line Items]
Ownership percentage	5.00%

Acquisitions, Investments, an40

Acquisitions, Investments, and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Apr. 30, 2015	Dec. 31, 2014
Investment [Line Items]
Gain (loss) on sale of investments	$ 216	$ 1,274
Other Income
Investment [Line Items]
Gain (loss) on sale of investments		$ 1,300
Neovasc
Investment [Line Items]
Warrants to purchase common shares				1,000,000
Cocrystal
Investment [Line Items]
Warrants to purchase common shares				1,000,000
ARNO
Investment [Line Items]
Warrants to purchase common shares				800,000
Sevion
Investment [Line Items]
Warrants to purchase common shares				100,000
MabVax
Investment [Line Items]
Warrants to purchase common shares			1,666,667	1,700,000
Rxi Pharmaceuticals Corporation
Investment [Line Items]
Ownership percentage	10.00%
ChromaDex
Investment [Line Items]
Ownership percentage	2.00%
ARNO
Investment [Line Items]
Ownership percentage	4.00%

Acquisitions, Investments, an41

Acquisitions, Investments, and Licenses - Pharmsynthez transactions Narrative (Details) shares in Millions, RUB in Millions, $ in Millions	1 Months Ended			6 Months Ended		12 Months Ended
	Jan. 31, 2014shares	Apr. 30, 2013USD ($)shares	Apr. 30, 2013RUBshares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2014USD ($)
Investment [Line Items]
Deferred revenue				$ 272.4			$ 6.7
Pharmsynthez
Investment [Line Items]
Asset purchase agreement		$ 9.6
Number of shares purchased | shares		13.6	13.6
Number of share options received in purchase agreement | shares		12	12
Proceeds to be received from sale of proprietary technology			RUB 265			$ 8.1
Shares received in satisfaction of notes receivable | shares	12
Deferred revenue		$ 9.5
Period for development of technology		3 years	3 years
Revenue related to our license agreements				0	$ 0.5
Revenue collaboration agreement, offset to research and development				$ 0.5	$ 0.8

Acquisitions, Investments, an42

Acquisitions, Investments, and Licenses - Variable Interest Entities Narrative (Details) $ in Millions	1 Months Ended	6 Months Ended
	Jun. 30, 2012member	Jun. 30, 2015USD ($)shares
Variable Interest Entity [Line Items]
Ownership percentage by shareholder		68.40%
Zebra
Variable Interest Entity [Line Items]
Ownership percentage		28.00%
Series A Preferred Stock | Zebra
Variable Interest Entity [Line Items]
Investment owned, shares | shares		840,000
Restricted Stock | Zebra
Variable Interest Entity [Line Items]
Shares received as a gift | shares		900,000
SciVac
Variable Interest Entity [Line Items]
Stock ownership percentage		24.50%
SciVac | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Stock ownership percentage	50.00%	45.00%
Additional working capital | $		$ 7.6
Number of members of board of directors	5
Number of members of board of directors appointed by reporting entity	3
Percent of board of directors appointed by reporting entity	60.00%

Acquisitions, Investments, an43

Acquisitions, Investments, and Licenses - Schedule of Consolidated Assets and Non-Recourse Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2015		Dec. 31, 2014		Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents		$ 221,217	[1]	$ 96,907	[1]	$ 134,010	$ 185,798
Accounts receivable, net	[1]	26,980		19,969
Inventory, net	[1]	20,519		16,604
Prepaid expenses and other current assets	[1]	9,623		9,389
Total current assets	[1]	278,339		142,869
Property, plant and equipment, net	[1]	23,405		16,411
Intangible assets, net	[1]	94,247		62,649
Goodwill	[1]	289,607		224,292
Other assets	[1]	6,013		5,838
Total assets	[1]	1,525,491		1,267,664
Current liabilities:
Accounts payable	[1]	16,039		8,744
Accrued expenses	[1]	149,843		60,912
Total current liabilities	[1]	180,481		83,111
Other long-term liabilities	[1]	408,821		217,358
Total liabilities	[1]	698,505		431,923
SciVac | Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents		21		393
Accounts receivable, net		304		316
Inventory, net		1,433		1,649
Prepaid expenses and other current assets		774		718
Total current assets		2,532		3,076
Property, plant and equipment, net		1,791		1,725
Intangible assets, net		843		875
Goodwill		1,602		1,553
Other assets		368		384
Total assets		7,136		7,613
Current liabilities:
Accounts payable		900		445
Accrued expenses		4,476		4,446
Notes payable		5,409		5,189
Total current liabilities		10,785		10,080
Other long-term liabilities		1,884		2,042
Total liabilities		$ 12,669		$ 12,122
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Debt - Narrative (Details)

Debt - Narrative (Details)	Aug. 30, 2013USD ($)conversion_rightshares	Jan. 31, 2013USD ($)$ / shares	May. 31, 2015USD ($)shares	Jun. 30, 2014USD ($)shares	Jan. 31, 2013USD ($)$ / shares	Jun. 30, 2015USD ($)dinstitutionconversion_right$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)institution
Debt Instrument [Line Items]
Interest paid						$ 1,724,000	$ 2,771,000
Gains (losses) on extinguishment of debt						(291,000)	$ 2,668,000
Gain (loss) on embedded derivative						$ 68,000,000
Number of financial institutions | institution						8		12
OPKO Health Europe
Debt Instrument [Line Items]
Long-term Debt						$ 3,225,000		$ 3,043,000
Weighted average interest rate						3.20%		3.40%
Minimum | OPKO Health Europe
Debt Instrument [Line Items]
Variable interest rates						2.70%
Maximum | OPKO Health Europe
Debt Instrument [Line Items]
Variable interest rates						6.30%
Notes
Debt Instrument [Line Items]
Convertible notes, conversion						$ 41,442,000
Long-term Debt						$ 109,203,000		$ 131,454,000
Notes | Notes Due February 1, 2033
Debt Instrument [Line Items]
Debt face amount		$ 175,000,000			$ 175,000,000
Interest rate of notes payable		3.00%			3.00%	3.00%
Equivalent redemption price		100.00%			100.00%
Conversion Rate	141.4827	141.48				141.4827
Conversion Price | $ / shares		$ 7.07			$ 7.07	$ 7.07
Number of trading days | d						20
Convertible debt, threshold percentage of stock price trigger					130.00%	130.00%
Number of consecutive trading days applicable conversion price						30 days
Conversion right triggered | conversion_right	1					1
Convertible notes, conversion	$ 16,900,000			$ 70,400,000		$ 36,400,000
Convertible debt, stock issued from conversion | shares	2,396,145		726,036
Interest paid				$ 800,000		200,000
Gains (losses) on extinguishment of debt			$ 30,000			$ (300,000)
Converted amount			$ 5,000,000
Common stock trigger price | $ / shares						$ 9.19
Long-term Debt						$ 46,200,000
Notes | Notes Due February 1, 2033 | Minimum
Debt Instrument [Line Items]
Number of trading days applicable conversion price					20 days
Notes | Notes Due February 1, 2033 | Maximum
Debt Instrument [Line Items]
Number of consecutive trading days applicable conversion price					30 days
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019
Debt Instrument [Line Items]
Equivalent redemption price					100.00%
Line of Credit
Debt Instrument [Line Items]
Weighted average interest rate						5.70%		6.10%
Common stock investments, available for sale | Notes | Notes Due February 1, 2033
Debt Instrument [Line Items]
Convertible debt, stock issued from conversion | shares				10,974,431		5,363,896

Debt - Notes (Details)

Debt - Notes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Debt Instrument [Roll Forward]
Change in fair value of embedded derivative	$ (16,556)	$ 10,967	$ (66,344)	$ 594
Notes
Debt Instrument [Roll Forward]
Embedded derivatives, beginning balance			65,947
Convertible notes, beginning balance			87,642
Discount, beginning balance			(22,135)
Total, beginning balance			131,454
Amortization of debt discount			1,680
Change in fair value of embedded derivative			67,950
Embedded conversion option, conversion			(60,346)
Convertible notes, conversion			(41,442)
Discount, conversion			9,907
Conversion			(91,881)
Embedded derivatives, ending balance	73,551		73,551
Convertible notes, ending balance	46,200		46,200
Discount, ending balance	(10,548)		(10,548)
Total, ending balance	$ 109,203		$ 109,203

Debt - Inputs Used In Lattice M

Debt - Inputs Used In Lattice Model (Details) - Notes - Notes Due February 1, 2033	Aug. 30, 2013	Jan. 31, 2013$ / shares	Jun. 30, 2015$ / shares
Debt Instrument [Line Items]
Stock price			$ 16.08
Conversion Rate	141.4827	141.48	141.4827
Conversion Price		$ 7.07	$ 7.07
Maturity date			Feb. 1, 2033
Risk-free interest rate			1.19%
Estimated stock volatility			41.00%
Estimated credit spread			11.33%

Debt - Fair Value Of Embedded D

Debt - Fair Value Of Embedded Derivatives (Details) - Notes - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair value of Notes:
With the embedded derivatives	$ 107,743
Without the embedded derivatives	34,192
Estimated fair value of the embedded derivatives	$ 73,551	$ 65,947

Debt - Lines Of Credit (Details

Debt - Lines Of Credit (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Credit line capacity	$ 13,867,000
Balance Outstanding	$ 8,358,000	$ 7,658,000
Itau Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	6.00%
Credit line capacity	$ 1,800,000
Balance Outstanding	$ 1,171,000	965,000
Bank of Chile
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	5.50%
Credit line capacity	$ 2,250,000
Balance Outstanding	$ 1,572,000	1,410,000
BICE Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	6.16%
Credit line capacity	$ 2,300,000
Balance Outstanding	$ 1,088,000	1,249,000
BBVA Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	5.00%
Credit line capacity	$ 2,300,000
Balance Outstanding	$ 1,552,000	795,000
Penta Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	7.58%
Credit line capacity	$ 1,200,000
Balance Outstanding	$ 631,000	1,008,000
Security Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	6.16%
Credit line capacity	$ 940,000
Balance Outstanding	$ 305,000	361,000
Estado Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	5.30%
Credit line capacity	$ 2,800,000
Balance Outstanding	$ 2,039,000	1,870,000
BBVA Bank
Line of Credit Facility [Line Items]
Interest rate on borrowings at June 30, 2015	4.75%
Credit line capacity	$ 277,000
Balance Outstanding	$ 0	$ 0

Debt - Mortgage Notes And Other

Debt - Mortgage Notes And Other Debt (Details) - USD ($) $ in Thousands		Jun. 30, 2015	Dec. 31, 2014
Mortgage notes and other debt payables
Current portion of notes payable	[1]	$ 14,599	$ 13,455
Other long-term liabilities		2,148	2,434
OPKO Health Europe
Mortgage notes and other debt payables
Current portion of notes payable		832	608
Other long-term liabilities		2,393	2,435
Total mortgage notes and other debt		$ 3,225	$ 3,043
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Accumulated Other Comprehensi50

Accumulated Other Comprehensive Income (Loss) (Details) $ in Thousands		6 Months Ended
		Jun. 30, 2015USD ($)
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning Balance	[1]	$ (12,392)
Other comprehensive income before reclassifications, net of tax		(6,488)
Amounts reclassified from accumulated other comprehensive income, net of tax		0
Net other comprehensive loss		(6,488)
Ending Balance	[1]	(18,880)
Foreign currency
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning Balance		(6,717)
Other comprehensive income before reclassifications, net of tax		(4,547)
Amounts reclassified from accumulated other comprehensive income, net of tax		0
Net other comprehensive loss		(4,547)
Ending Balance		(11,264)
Unrealized gain (loss) in Accumulated OCI
Accumulated Other Comprehensive Income (Loss), Net [Rollforward]
Beginning Balance		(5,675)
Other comprehensive income before reclassifications, net of tax		(1,941)
Amounts reclassified from accumulated other comprehensive income, net of tax		0
Net other comprehensive loss		(1,941)
Ending Balance		$ (7,616)
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Fair Value Measurements - Summa

Fair Value Measurements - Summary Of Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 15,404	$ 12,904
Gross unrealized gains in Accumulated OCI	898	509
Gross unrealized losses in Accumulated OCI	(7,119)	(4,573)
Gain/(Loss) in Accumulated Deficit	4,602	3,232
Fair value	13,785	12,072
Common stock investments, available for sale
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	11,479	11,479
Gross unrealized gains in Accumulated OCI	898	293
Gross unrealized losses in Accumulated OCI	(7,119)	(4,573)
Gain/(Loss) in Accumulated Deficit	(1,442)	(1,441)
Fair value	3,816	5,758
Common stock options/warrants
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,925	1,425
Gross unrealized gains in Accumulated OCI	0	216
Gross unrealized losses in Accumulated OCI	0	0
Gain/(Loss) in Accumulated Deficit	6,044	4,673
Fair value	$ 9,969	$ 6,314

Fair Value Measurements - Asset

Fair Value Measurements - Assets And Liabilities Measured At Fair Value (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Assets:
Total assets	$ 66,463	$ 83,394
Liabilities:
Total liabilities	147,880	137,514
Level 1
Assets:
Total assets	56,379	77,044
Level 2
Assets:
Total assets	10,084	6,350
Liabilities:
Total liabilities	0
Level 3
Assets:
Total assets		0
Liabilities:
Total liabilities	147,880	137,514
Embedded conversion option
Liabilities:
Total liabilities	73,551	65,947
Embedded conversion option | Level 3
Liabilities:
Total liabilities	73,551	65,947
Contingent consideration | CURNA
Liabilities:
Total liabilities	433	440
Contingent consideration | CURNA | Level 3
Liabilities:
Total liabilities	433	440
Contingent consideration | OPKO Diagnostics
Liabilities:
Total liabilities	13,342	13,578
Contingent consideration | OPKO Diagnostics | Level 3
Liabilities:
Total liabilities	13,342	13,578
Contingent consideration | OPKO Renal
Liabilities:
Total liabilities	60,090	55,780
Contingent consideration | OPKO Renal | Level 3
Liabilities:
Total liabilities	60,090	55,780
Contingent consideration | OPKO Health Europe
Liabilities:
Total liabilities	464	1,769
Contingent consideration | OPKO Health Europe | Level 3
Liabilities:
Total liabilities	464	1,769
Money market funds
Assets:
Total assets	52,563	71,286
Money market funds | Level 1
Assets:
Total assets	52,563	71,286
Common stock investments, available for sale
Assets:
Total assets	3,816	5,758
Common stock investments, available for sale | Level 1
Assets:
Total assets	3,816	5,758
Common stock options/warrants
Assets:
Total assets	9,969	6,314
Common stock options/warrants | Level 2
Assets:
Total assets	9,969	6,314
Forward contracts
Assets:
Total assets	115	36
Forward contracts | Level 2
Assets:
Total assets	$ 115	$ 36

Fair Value Measurements - Notes

Fair Value Measurements - Notes (Details) - Notes $ in Thousands	Jun. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2033 Senior Notes	$ 34,192
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2033 Senior Notes	34,192
Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
2033 Senior Notes	$ 35,652

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Reconciliation (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Contingent consideration
Total losses (gains) for the period:
Beginning Balance	$ 71,567
Included in results of operations	4,836
Foreign currency impact	(261)
Payments	(1,813)
Ending Balance	74,329
Embedded conversion option
Total losses (gains) for the period:
Beginning Balance	65,947
Included in results of operations	67,950
Conversion	(60,346)
Ending Balance	$ 73,551

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of increase in discount rate	1.00%
Decrease in contingent consideration on discount rates increase	$ 1.2
Percentage of decrease in future sales	10.00%
Decrease of estimated future sales in amount	$ 1.7
Contingent consideration	$ 74.3	$ 71.6
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rates related to consideration	6.00%
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rates related to consideration	27.00%
Accrued Expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 41.1	27.4
Other Noncurrent Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 33.2	$ 44.2

Derivative Contracts - Balance

Derivative Contracts - Balance Sheet Component (Details) - Not Designated as Hedging Instrument - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Common stock options/warrants | Investments, net
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	$ 9,969	$ 6,314
Embedded conversion option | 2033 Senior Notes, net of discount and estimated fair value of embedded derivatives
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	73,551	65,947
Forward contracts
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	3,003	944
Forward contracts | Unrealized gains on forward contracts are recorded in Prepaid expenses and other current assets. Unrealized losses on forward contracts are recorded in Accrued expenses.
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	$ 115	$ 36

Derivative Contracts - Derivati

Derivative Contracts - Derivative Gains (Losses) (Details) - Not Designated as Hedging Instrument - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015		Jun. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ (16,556)	$ 10,967	$ (66,344)		$ 594
Common stock options/warrants
Derivative Instruments, Gain (Loss) [Line Items]
Total	(2,446)	(860)	1,425	[1]	(263)	[1]
Notes
Derivative Instruments, Gain (Loss) [Line Items]
Total	(14,220)	11,882	(67,950)		770
Forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 110	$ (55)	$ 181		$ 87
[1]	Amount for 2014 includes the Pharmsynthez Note Receivable and the Purchase Option.

Derivative Contracts - Outstand

Derivative Contracts - Outstanding Forward Contracts (Details) - Not Designated as Hedging Instrument - Forward contracts - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Derivative [Line Items]
Contract value	$ 2,888	$ 908
Fair value	3,003	944
Effect on income (loss)	115	36
0 to 30
Derivative [Line Items]
Contract value	1,414	750
Fair value	1,466	780
Effect on income (loss)	$ 52	$ 30
Contract days until maturity, lower range
Contract days until maturity, higher range	30 days	30 days
31 to 60
Derivative [Line Items]
Contract value	$ 324	$ 90
Fair value	336	93
Effect on income (loss)	$ 12	$ 3
Contract days until maturity, lower range	31 days	31 days
Contract days until maturity, higher range	60 days	60 days
61 to 90
Derivative [Line Items]
Contract value	$ 939	$ 0
Fair value	981	0
Effect on income (loss)	$ 42	$ 0
Contract days until maturity, lower range	61 days	61 days
Contract days until maturity, higher range	90 days	90 days
91 to 120
Derivative [Line Items]
Contract value	$ 180	$ 68
Fair value	188	71
Effect on income (loss)	$ 8	$ 3
Contract days until maturity, lower range	91 days	91 days
Contract days until maturity, higher range	120 days	120 days
121 to 180
Derivative [Line Items]
Contract value		$ 0
Fair value		0
Effect on income (loss)		$ 0
Contract days until maturity, lower range		121 days
Contract days until maturity, higher range		180 days
More than 120
Derivative [Line Items]
Contract value	$ 31
Fair value	32
Effect on income (loss)	$ 1
Contract days until maturity, higher range	120 days
More than 180
Derivative [Line Items]
Contract value		$ 0
Fair value		0
Effect on income (loss)		$ 0
Contract days until maturity, higher range		180 days

Related Party Transactions (Det

Related Party Transactions (Details) $ / shares in Units, ft² in Thousands

Jan. 16, 2014USD ($)$ / sharesshares

May. 31, 2015USD ($)

Apr. 30, 2015USD ($)board_membershares

Feb. 28, 2014USD ($)

Jun. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Jun. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Dec. 31, 2012USD ($)

May. 28, 2015USD ($)ft²

Dec. 31, 2014shares

Aug. 31, 2013

Jan. 31, 2013USD ($)

Notes | Notes Due February 1, 2033

Related Party Transaction [Line Items]

Debt face amount

$ 175,000,000

MabVax

Related Party Transaction [Line Items]

Invested in common shares

$ 2,500,000

Investment owned, shares | shares

33,333

Warrants to purchase common shares | shares

1,666,667

1,700,000

Alloted number of board members appointed | board_member

2

ARNO

Related Party Transaction [Line Items]

Warrants to purchase common shares | shares

800,000

Ownership percentage

4.00%

4.00%

Zebra

Related Party Transaction [Line Items]

Ownership percentage

28.00%

28.00%

Sevion

Related Party Transaction [Line Items]

Warrants to purchase common shares | shares

100,000

Ownership percentage

4.00%

4.00%

Chromadex Corporation

Related Party Transaction [Line Items]

Ownership percentage

2.00%

2.00%

Biozone Pharmaceuticals Inc

Related Party Transaction [Line Items]

Invested in common shares

$ 1,700,000

Cocrystal

Related Party Transaction [Line Items]

Warrants to purchase common shares | shares

1,000,000

Ownership percentage

8.00%

8.00%

Neovasc

Related Party Transaction [Line Items]

Warrants to purchase common shares | shares

1,000,000

Ownership percentage

5.00%

5.00%

Dr Frost | OPKO Biologics

Related Party Transaction [Line Items]

Beneficially owned held by members

5.00%

Dr. Hsiao and Mr. Rubin | OPKO Biologics

Related Party Transaction [Line Items]

Beneficially owned held by members

5.00%

Frost Gamma Investments Trust and Hsu Gamma Investment, L.P. | Notes | Notes Due February 1, 2033

Related Party Transaction [Line Items]

Debt face amount

$ 175,000,000

Teva | FineTech

Related Party Transaction [Line Items]

Sale of API to TEVA

$ 0

$ 300,000

Frost Real Estate Holdings LLC

Related Party Transaction [Line Items]

Area of real estate property (in square feet) | ft²

25

Payments per month in first year

$ 66,000

Payments per month in fifth year

75,000

Rent reduction

$ 216,000

FTC Filings | Dr Frost

Related Party Transaction [Line Items]

Payments for filing fees

$ 280,000

Equity Method Investee | Sevion

Related Party Transaction [Line Items]

Private placement financing

$ 500,000

Equity Method Investee | Biozone

Related Party Transaction [Line Items]

Investment owned, shares | shares

1,000,000

Warrants to purchase common shares | shares

1,000,000

Additional investment in common shares

$ 500,000

Private placement financing

$ 2,750,000

Warrants duration

10 years

Warrants exercisable price (in USD per share) | $ / shares

$ 0.50

Reimbursement Of Travel Expense | Dr Frost

Related Party Transaction [Line Items]

Reimbursement paid to related party for travel

$ 167,000

$ 49,000

$ 293,000

$ 62,000

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended	6 Months Ended
	Jul. 31, 2012claim	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration		$ 74.3	$ 71.6
Number of claims included in post-payment audit | claim	183
Fixed purchase provisions		19.2
Accrued Liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration		41.1	27.4
Other Noncurrent Liabilities
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration		33.2	$ 44.2
Merck [Member]
Business Acquisition, Contingent Consideration [Line Items]
Additional milestone payment		$ 25

Strategic Alliances (Details)

Strategic Alliances (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended			6 Months Ended
	Jan. 31, 2015	Dec. 31, 2010	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue			$ 272,400			$ 272,400		$ 6,700
Grant repayment			0	$ 25,900	$ 0	25,889	$ 0
Pfizer | Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment	$ 295,000
Additional milestone payment to be received	275,000
Revenue from sale of intellectual property						30,200
Deferred revenue			264,800			264,800
Tesaro
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payment to be received		$ 30,000
Upfront payment under license agreements		6,000
Milestone payment received						5,000
Additional milestone payment		$ 85,000				25,000
Period from first commercial sale		12 years
Accrued Expenses | Pfizer | Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue			70,600			70,600
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue			$ 194,200			$ 194,200
Minimum | Pfizer | Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment ranges	20,000
Maximum | Pfizer | Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment ranges	$ 90,000
Rxi Pharmaceuticals Corporation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments									$ 50,000

Segments - Narrative (Details)

Segments - Narrative (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015USD ($)SegmentCustomer	Jun. 30, 2014conversion_right	Dec. 31, 2014Customer
Segment Reporting Information [Line Items]
Number of reportable segments			2
Customer Concentration Risk | Sales Revenue, Net
Segment Reporting Information [Line Items]
Percentage of product revenue contributed by customer	42.00%	21.00%	42.00%	15.00%
Number of customer represented | conversion_right				1
Customer Concentration Risk | Accounts Receivable
Segment Reporting Information [Line Items]
Number of customer represented | Customer			0		0
Intersegment Elimination
Segment Reporting Information [Line Items]
Inter-segment sales | $			$ 0
Inter-segment allocation of interest expense | $			$ 0
Pharmaceuticals
Segment Reporting Information [Line Items]
Number of operating segments			2
Diagnostics
Segment Reporting Information [Line Items]
Number of operating segments			2

Segments (Details)

Segments (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Product revenues		$ 22,848	$ 21,392	$ 38,334	$ 41,219
Revenue from services		1,908	2,153	3,977	4,123
Revenue from transfer of intellectual property		17,673	0	30,202	476
Operating (loss) income		(25,409)	(34,885)	(82,322)	(65,160)
Depreciation and amortization		4,152	4,027	7,685	7,591
Net loss from investment in investees		(804)	(370)	(2,565)	(2,426)
Total revenues		42,429	23,545	72,513	45,818
Assets	[1]	1,525,491		1,525,491		$ 1,267,664
Goodwill	[1]	289,607		289,607		224,292
United States
Segment Reporting Information [Line Items]
Total revenues		2,525	2,153	5,019	4,599
Ireland
Segment Reporting Information [Line Items]
Total revenues		19,376	0	31,480	0
Chile
Segment Reporting Information [Line Items]
Total revenues		8,698	7,852	15,150	15,136
Spain
Segment Reporting Information [Line Items]
Total revenues		4,920	5,666	8,857	11,815
Israel
Segment Reporting Information [Line Items]
Total revenues		5,942	6,307	10,155	10,853
Mexico
Segment Reporting Information [Line Items]
Total revenues		968	1,546	1,852	3,377
Other
Segment Reporting Information [Line Items]
Total revenues		0	21	0	38
Corporate
Segment Reporting Information [Line Items]
Revenue from services		60	60	120	120
Revenue from transfer of intellectual property		0	0	0	0
Operating (loss) income		(12,905)	(7,038)	(22,882)	(13,174)
Depreciation and amortization		27	24	46	48
Net loss from investment in investees		0	0	0	0
Assets		130,638		130,638		95,094
Goodwill		0		0		0
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating (loss) income		(746)	(674)	(1,281)	(1,163)
Pharmaceuticals | Operating Segments
Segment Reporting Information [Line Items]
Product revenues		22,848	21,392	38,334	41,219
Revenue from services		0	0	0	0
Revenue from transfer of intellectual property		17,673	0	30,202	285
Operating (loss) income		(4,660)	(20,368)	(42,584)	(36,941)
Depreciation and amortization		2,371	2,287	4,138	4,135
Net loss from investment in investees		(804)	(370)	(2,565)	(2,426)
Assets		1,290,366		1,290,366		1,064,498
Goodwill		238,642		238,642		173,327
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Revenue from services		1,848	2,093	3,857	4,003
Revenue from transfer of intellectual property		0	0	0	191
Operating (loss) income		(7,098)	(6,805)	(15,575)	(13,882)
Depreciation and amortization		1,754	1,716	3,501	3,408
Net loss from investment in investees		0	$ 0	0	$ 0
Assets		104,487		104,487		108,072
Goodwill		$ 50,965		$ 50,965		$ 50,965
[1]	As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Millions	Aug. 30, 2013conversion_right	Jan. 31, 2013$ / shares	Jul. 31, 2015USD ($)	Jan. 31, 2013$ / shares	Jun. 30, 2015dconversion_right$ / shares
Convertible Notes | Notes Due February 1, 2033
Debt Instrument [Line Items]
Common stock trigger price					$ 9.19
Convertible debt, threshold percentage of stock price trigger				130.00%	130.00%
Conversion Price		$ 7.07		$ 7.07	$ 7.07
Number of trading days | d					20
Number of consecutive trading days applicable conversion price					30 days
Conversion right triggered | conversion_right	1				1
Conversion Rate	141.4827	141.48			141.4827
OPKO Renal | Subsequent Event
Debt Instrument [Line Items]
Obligation payment | $			$ 20